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1. Executive summary
Hyperglycemia is one of the most common medical conditions 
women encounter during pregnancy. The International Diabetes 
Federation (IDF) estimates that one in six live births (16.8%) are to 
women with some form of hyperglycemia in pregnancy. While 16% 
of these cases may be due to diabetes in pregnancy (either pre-
existing diabetes—type 1 or type 2—which antedates pregnancy 
or is first identified during testing in the index pregnancy), the 
majority (84%) is due to gestational diabetes mellitus (GDM).
The occurrence of GDM parallels the prevalence of impaired 
glucose tolerance (IGT), obesity, and type 2 diabetes mellitus 
(T2DM) in a given population. These conditions are on the rise 
globally. Moreover, the age of onset of diabetes and pre-diabetes 
is declining while the age of childbearing is increasing. There is 
also an increase in the rate of overweight and obese women of 
reproductive age; thus, more women entering pregnancy have 
risk factors that make them vulnerable to hyperglycemia during 
pregnancy.
GDM is associated with a higher incidence of maternal 
morbidity including cesarean deliveries, shoulder dystocia, birth 
trauma, hypertensive disorders of pregnancy (including pre-
eclampsia), and subsequent development of T2DM. Perinatal 
and neonatal morbidities also increase; the latter include 
macrosomia, birth injury, hypoglycemia, polycythemia, and 
hyperbilirubinemia. Long-term sequelae in offspring with in 
utero exposure to maternal hyperglycemia may include higher 
risks for obesity and diabetes later in life.
In most parts of low-, lower middle-, and upper middle-
income countries (which contribute to over 85% of the annual 
global deliveries), the majority of women are either not screened 
or improperly screened for diabetes during pregnancy—even 
though these countries account for 80% of the global diabetes 
burden as well as 90% of all cases of maternal and perinatal 
deaths and poor pregnancy outcomes.
Given the interaction between hyperglycemia and poor 
pregnancy outcomes, the role of in utero imprinting in 
increasing the risk of diabetes and cardiometabolic disorders 
in the offspring of mothers with hyperglycemia in pregnancy, 
as well as increasing maternal vulnerability to future diabetes 
and cardiovascular disorders, there needs to be a greater global 
focus on preventing, screening, diagnosing, and managing 
hyperglycemia in pregnancy. The relevance of GDM as a priority 
for maternal health and its impact on the future burden of 
noncommunicable diseases is no longer in doubt, but how best 
to deal with the issue remains contentious as there are many 
gaps in knowledge on how to prevent, diagnose, and manage 
GDM to optimize care and outcomes. These must be addressed 
through future research.
The International Federation of Gynecology and Obstetrics 
(FIGO) brought together international experts to develop a 
document to frame the issues and suggest key actions to address 
the health burden posed by GDM. FIGO’s objective, as outlined 
in this document, is: (1) to raise awareness of the links between 
hyperglycemia and poor maternal and fetal outcomes as well as 
to the future health risks to mother and offspring, and demand 
a clearly defined global health agenda to tackle this issue; and 
(2) to create a consensus document that provides guidance for 
testing, management, and care of women with GDM regardless 
of resource setting and to disseminate and encourage its use.
Despite the challenge of limited high-quality evidence, the 
document outlines current global standards for the testing, 
management, and care of women with GDM and provides 
pragmatic recommendations, which because of their level of 
acceptability, feasibility, and ease of implementation, have the 
potential to produce significant impact. Suggestions are provided 
for a variety of different regional and resource settings based 
on their financial, human, and infrastructure resources, as well 
as for research priorities to bridge the current knowledge and 
evidence gap.
To address the issue of GDM, FIGO recommends the following:
Public health focus: There should be greater international 
attention paid to GDM and to the links between maternal 
health and noncommunicable diseases on the sustainable 
developmental goals agenda. Public health measures to increase 
awareness, access, affordability, and acceptance of preconception 
counselling, and prenatal and postnatal services for women of 
reproductive age must be prioritized.
Universal testing: All pregnant women should be tested for 
hyperglycemia during pregnancy using a one-step procedure 
and FIGO encourages all countries and its member associations 
to adapt and promote strategies to ensure this.
Criteria for diagnosis: The WHO criteria for diagnosis 
of diabetes mellitus in pregnancy [1] and the WHO and the 
International Association of Diabetes in Pregnancy Study Groups 
(IADPSG) criteria for diagnosis of GDM [1,2] should be used 
when possible. Keeping in mind the resource constraints in 
many low-resource countries, alternate strategies described in 
the document should also be considered equally acceptable.
Diagnosis of GDM: Diagnosis should ideally be based on 
laboratory results of venous serum or plasma samples that are 
properly collected, transported, and tested. Though plasma-
calibrated handheld glucometers offer results that are less 
accurate and precise than those from quality-controlled labora-
tories, it is acceptable to use such devices for the diagnosis of 
glucose intolerance in pregnancy in locations where laboratory 
support is either unavailable or at a site remote to the point of 
care.
Management of GDM: Management should be in accordance 
with available national resources and infrastructure even if the 
specific diagnostic and treatment protocols are not supported by 
high-quality evidence, as this is preferable to no care at all.
Lifestyle management: Nutrition counselling and physical 
activity should be the primary tools in the management of GDM. 
Women with GDM must receive practical nutritional education 
and counselling that will empower them to choose the right 
quantity and quality of food and level of physical activity. They 
should be advised repeatedly during pregnancy to continue the 
same healthy lifestyle after delivery to reduce the risk of future 
obesity, T2DM, and cardiovascular diseases.
Pharmacological management: If lifestyle modification 
alone fails to achieve glucose control, metformin, glyburide, or 
insulin should be considered as safe and effective treatment 
options for GDM.
Postpartum follow-up and linkage to care: Following a 
pregnancy complicated by GDM, the postpartum period provides 
an important platform to initiate beneficial health practices for 
both mother and child to reduce the future burden of several 
noncommunicable diseases. Obstetricians should establish 
links with family physicians, internists, pediatricians, and other 
healthcare providers to support postpartum follow-up of GDM 
mothers and their children. A follow-up program linked to the 
child’s vaccination and regular health check-up visits provides 
an opportunity for continued engagement with the high risk 
mother−child pair.
Future research: There should be greater international 
research collaboration to address the knowledge gaps to 
better understand the links between maternal health and 
noncommunicable diseases. Evidence-based findings are 
urgently needed to provide best practice standards for testing, 
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management, and care of women with GDM. Cost-effectiveness 
models must be used for countries to make the best choices for 
testing and management of GDM given their specific burden of 
disease and resources.
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This document is directed at multiple stakeholders with the 
intention of bringing attention to hyperglycemia in pregnancy, 
with particular focus on gestational diabetes. GDM is a hitherto 
less-prioritized but common medical condition associated 
with pregnancy that has serious consequences. This document 
proposes to create a global framework for action to improve the 
diagnosis and care of women with GDM.
The intended target audience includes:
Healthcare providers: All those who are qualified to care 
for women with GDM and their offspring (obstetricians, 
diabetologists, endocrinologists, internists, pediatricians, neo-
natologists and general practitioners, midwives, nurses, advance 
practice clinicians, nutritionists, pharmacists, community health 
workers, laboratory technicians, etc.)
Healthcare delivery organizations and providers: govern-
ments, federal and state legislators, healthcare management 
organizations, health insurance organizations, international 
development agencies, and nongovernmental organizations.
Professional organizations: international, regional, and 
national professional organizations of obstetricians and gyne-
cologists, endocrinologists, diabetologists, internists, family 
practi tioners, pediatricians, neonatologists, and worldwide 
national organizations dedicated to the care of pregnant women 
with diabetes.
2. The target audience of the FIGO Initiative on gestational diabetes mellitus
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In assessing the quality of evidence and grading of strength 
of recommendations, the document follows the terminology 
proposed by the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) Working Group (http://
www.gradeworkinggroup.org/index.htm). This system uses 
consistent language and graphical descriptions for the strength 
and quality of the recommendations and the evidence on which 
they are based. Strong recommendations are numbered as 1 and 
conditional (weak) recommendations are numbered 2. For the 
quality of evidence, cross-filled circles are used:  denotes 
very low-quality evidence;  low quality;  moderate 
quality; and  high quality of evidence (Tables 1 and 2).
The overall quality of evidence was assessed for each of the 
recommendations and expressed using four levels of quality: 
very low, low, moderate, and high (Table 2). Considerations 
for quality of evidence include primarily the study design and 
methodology. As such, evidence based on randomized controlled 
trials is considered high-quality evidence, observational studies 
provide moderate or low quality of evidence, and all others are 
very low. However, other parameters must be considered while 
assessing the level of evidence: risk of bias, study limitations, 
directness, consistency of results, precision, publication bias, 
indirectness of evidence, and scarcity of evidence. Therefore, a 
limited randomized trial is downgraded and level of evidence 
is considered moderate or low. These limitations include loss 
to follow-up, inadequacy of allocation concealment, or an 
unblinded study with subjective outcomes susceptible to bias. 
Similarly, an observational study may be upgraded if it supplies 
large and consistent estimates of the magnitude of a treatment 
effect.
Additionally, each recommendation is denoted with its 
strength (strong or weak) while considering the balance of 
desirable and undesirable consequences, quality of evidence, 
values and preferences, and resource use (Table 2). Therefore, 
the quality of evidence is only one possible consideration 
for the strength of evidence. The decision to apply a possible 
examination or intervention is also based on potential risk−
benefit, cost, and resource allocation. Some recommendations 
may be based on low-quality evidence but still represent a 
benefit that outweighs the risks and burdens, and therefore may 
be strongly recommended.
A pregnant woman waits for her gestational diabetes screening in Tamil Nadu, 
India. Photograph by Jesper Westley for the World Diabetes Foundation.
3. Quality assessment of evidence and grading of strength of recommendations
Table 1
Interpretation of strong and conditional (weak) recommendations according to GRADE.a
1 = Strong recommendation phrased as “we recommend” 2 = Conditional (weak) recommendation phrased as “we suggest”
For patients Nearly all patients in this situation would accept the 
recommended course of action. Formal decision aids are not 
needed to help patients make decisions consistent with their 
values and preferences.
Most patients in this situation would accept the suggested course of 
action.
For clinicians According to the guidelines, performance of the recommended 
action could be used as a quality criterion or performance 
indicator, unless the patent refuses.
Decision aids may help patients make a management decision 
consistent with their values and preferences.
For policy makers The recommendation can be adapted as policy in most 
situations.
Stakeholders need to discuss the suggestion.
aAdapted with permission from Swiglo et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using 
the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93(3):666-73. Copyright Endocrine Society 
(2008).
Note: Both caregivers and care recipients need to be involved in the decision-making process before adopting recommendations.
Table 2
Interpretation of quality of evidence levels according to GRADE. a
Level of evidence Definition
High

We are very confident that the true effect corresponds to that of the estimated effect.
Moderate





Our confidence in the estimated effect is limited. The true effect could be substantially different from the estimated effect.
Very low

We have very little confidence in the estimated effect. The true effect is likely to be substantially different from the estimated effect.
aAdapted with permission from Balshem et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6. Copyright Elsevier (2011).
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4.1. Introduction
Despite decades of research, multiple studies, and numerous 
global consensus conferences, aspects of hyperglycemia in 
pregnancy—particularly those related to classification and 
diagnosis of GDM—remain controversial [1]. GDM diagnosis 
was originally linked to an increased risk of maternal diabetes 
in later life. Due to remarkable advances in recent years, the 
metabolic processes that occur during pregnancy and their 
effect on intrauterine fetal development have been clarified. 
Consequently, clinicians are more aware of the need to precisely 
identify and manage metabolic dysfunction in pregnancy 
manifested especially by aberrant glucose metabolism. This has 
led to an increased focus on the ability to predict and prevent 
many potential fetal and maternal complications in the index 
pregnancy [1].
4.2. Classification of hyperglycemia in pregnancy and 
definition of GDM
The definition of GDM is evolving. Until recently, the accepted 
definition was “any degree of glucose intolerance with onset or 
first recognition during pregnancy” [2]. Because this definition 
includes women with pre-existing diabetes who were not 
identified prior to pregnancy and because this definition blurs the 
line between morbidities associated with diabetes in pregnancy 
and gestational diabetes, renewed efforts are being made to 
improve the definition and classification of hyperglycemia during 
pregnancy. These efforts are also spurred by the increasing 
prevalence of diabetes and GDM [3] and of greater prevalence of 
maternal and fetal complications resulting from diabetes mellitus 
antedating pregnancy. Therefore, hyperglycemia first detected at 
any time during pregnancy should be classified either as diabetes 
mellitus in pregnancy (DIP) or GDM [4].
4.3. Diabetes in pregnancy
DIP may either have been pre-existing diabetes (type 1 or 
type 2) antedating pregnancy, or diabetes first diagnosed during 
pregnancy (Figure 1).
Notwithstanding its severity, hyperglycemia that is already 
present at conception and embryogenesis increases the 
women’s vulnerability and risk of complications. A woman 
with undiagnosed diabetes antedating pregnancy may also 
have undiagnosed diabetic complications including retinopathy 
and nephropathy, which markedly increase pregnancy risks 
[5]. Furthermore, hyperglycemia during the critical period of 
organogenesis may lead to a high risk of spontaneous abortions 
and congenital anomalies. Diabetes in pregnancy, because of 
the attendant greater risk of hyperglycemia, may also result in 
aberrations in fetal growth and macrosomia. This can lead to 
additional short-term complications, for example, obstructed 
labor, shoulder dystocia, neonatal hypoglycemia, or risk of 
neurological damage. Moreover, there is a risk of onset or 
exacerbation of microvascular complications, such as retinopathy 
or nephropathy during pregnancy. For these reasons, ensuring 
meticulous glucose control before conception and throughout 
pregnancy is recommended.
The age at onset of T2DM is decreasing globally and many 
women with previously unknown T2DM may become pregnant, 
with their diabetes first detected during routine testing in 
pregnancy. Alternatively, women at high risk of diabetes may 
be unable to withstand the metabolic stress of pregnancy and 
develop diabetes for the first time during pregnancy (Figure 2).
When the level of hyperglycemia first detected by testing at 
any time during the course of pregnancy meets the criteria for 
diagnosis of diabetes in the nonpregnant state, the condition 
is called DIP. Those criteria are: fasting plasma glucose (FPG) 
≥7.0 mmol/L or 126 mg/dL, and/or 2-hour 75-g oral glucose 
tolerance test (OGTT) value ≥11.1 mmol/L or 200 mg/dL, or 
random plasma glucose (RPG) ≥11.1 mmol/L or 200 mg/dL 
associated with signs and symptoms of diabetes. In DIP the 
vulnerability to complications is high because of the degree 
of hyperglycemia and the uncertainty as to whether the onset 
of hyperglycemia was prior to pregnancy or developed during 
early pregnancy. While diabetes diagnosed for the first time in 
pregnancy might be type1 or type 2, a diagnosis of type 2 is more 
likely. Compared with gestational diabetes, DIP is more likely to 
be detected as early as the first trimester provided appropriate 
testing is undertaken.
Hyperglycemia in pregnancy
Diabetes in pregnancy Gestaonal diabetes mellitus 
Diagnosed before the start of 
pregnancy 
Diagnosed for the ﬁrst me 
during pregnancy 
Type 1 Type 2 Type 1 Type 2 
Figure 1 Types of hyperglycemia in pregnancy.
4. Gestational diabetes mellitus: Background, definition, epidemiology, 
pathophysiology
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4.4. Gestational diabetes mellitus
When hyperglycemia detected during routine testing in 
pregnancy (generally between 24 and 28 weeks) does not meet 
the criteria of DIP it is called GDM. Diagnostic criteria and 
glucose cut-off values of GDM have been proposed by a number 
of organizations and professional groups and are described later 
in this document.
Due to its usual diagnosis and appearance later in pregnancy 
and less severe hyperglycemia, GDM implies a relatively milder 
form of hyperglycemia compared with that of DIP, but is 
nonetheless associated with a heightened risk of poor pregnancy 
outcome and future risk of diabetes and cardiovascular disease, 
and must be managed appropriately.
4.5. Epidemiology of GDM
Hyperglycemia is one of the most common medical 
conditions associated with pregnancy. The occurrence of GDM 
parallels the prevalence of impaired glucose tolerance (IGT), 
obesity, and T2DM in a given population, conditions that have 
risen globally during recent years [6–8]. Moreover, the age of 
onset of diabetes and pre-diabetes is declining, while the age of 
childbearing is rising in some countries. An increasing number of 
women of reproductive age are overweight and obese, thus more 
women entering pregnancy are vulnerable to hyperglycemia 
during pregnancy [9,10]. Global GDM prevalence rates show 
wide variations due to ethnicity and ethnic heterogeneity among 
different populations tested, which are further exacerbated 
by the different screening and diagnostic criteria used. GDM 
prevalence has been reported to vary between 1%−28% [11], 
while the International Diabetes Federation (IDF) estimates that 
one in six live births (16.8%) are to women with some form of 
hyperglycemia in pregnancy; 16% of these may be due to DIP, 
while the majority (84%) is related to GDM [8].
4.6. Risk factors
Publications show that risk factors for GDM include ethnicity 
and maternal factors such as older age, high parity, overweight 
and obesity, excessive weight gain in the index pregnancy, short 
stature, polycystic ovarian syndrome (PCOS), history of diabetes 
mellitus in first degree relatives, a past history of poor pregnancy 
outcome (abortion, fetal loss), macrosomia in previous and/or 
index pregnancy, GDM in a previous pregnancy, pre-eclampsia, 
and multifetal pregnancy [12]. In practice, slightly over half of 
the women with GDM have one or more of these risk factors, 
supporting the contention that identification of women who 
have GDM requires testing of all pregnant women [13–16].
4.7. Fetal and maternal morbidity associated with GDM
GDM is associated with a higher incidence of maternal 
morbidity, including cesarean deliveries, birth trauma, hyper-
tensive disorders of pregnancy (including pre-eclampsia), and 
subsequent development of T2DM. Perinatal and neonatal 
morbidities are also increased; the latter include macrosomia, 
shoulder dystocia and other birth injuries, respiratory distress, 
hypoglycemia, poly cythemia, and hyperbilirubinemia. Long-
term sequelae in off spring with in utero exposure to maternal 
hyperglycemia include higher risks of obesity, impaired glucose 
metabolism, and diabetes later in life. Table 3 summarizes the 
implications of GDM for both the mother and her offspring 
from fetal through adult life [17–25] and Figure 3 shows the 
short-term fetal and neonatal complications from intrauterine 
exposure to maternal hyperglycemia.
4.8. Pathophysiology
Pregnancy induces changes in maternal metabolism to 
accommodate and nurture the growth of the fetus in the womb 
from conception until full term birth. Even though the mother 
eats intermittently, the fetus must be nourished continuously. 
This is achieved by complex interactions of the feto-placental-
maternal unit, through secretion of hormones and metabolic 
mediators that create insulin resistance and modify maternal 
carbohydrate, lipid, and amino acid metabolism to ensure 
adequate nutrient supply to the fetus. These interactions are 
geared to create a harmonious balance between the needs of the 
mother, those of the fetus, and the mother’s ability to provide for 
 
Diabetes in pregnancy Gestaonal diabetes 
mellitus 
Pregnancy in previously known 
diabetes 
OR 
Hyperglycemia diagnosed for 
the ﬁrst me during pregnancy 
that meets WHO criterion for 
diabetes mellitus in the 
nonpregnant state 
May occur anyme during 
pregnancy including the ﬁrst 
trimester
Hyperglycemia during 
pregnancy that is not diabetes 
Hyperglycemia diagnosed for 
the ﬁrst me during 
pregnancy 
May occur anyme during 
pregnancy but most likely aer 
24 weeks
Figure 2 The difference between diabetes in pregnancy and gestational diabetes mellitus.
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these needs. In response to increasing insulin resistance, maternal 
insulin secretion increases and euglycemia is maintained. This is 
achieved at the cost of higher maternal insulin level and lower 
than normal nonpregnant fasting glucose levels.
Insulin resistance continues to increase as pregnancy advances 
and is well established by the 24th week. As long as the maternal 
pancreas continues to increase insulin production and secretion, 
hyperglycemia is prevented. When this capacity is overwhelmed 
by rising insulin resistance, maternal hyperglycemia ensues. 
Maternal insulin production capacity is thus put under immense 
stress during pregnancy. This explains why women with pre-
existing insulin resistance (e.g. overweight, obese, or excessive 
weight gain during pregnancy, PCOS, IGT, or metabolic syndrome) 
or those with lower ability to produce insulin (e.g. short stature, 
stunted) are more prone to GDM.
4.9. Fetal implications
Growth and development of the human conceptus occurs 
within the metabolic milieu provided by the mother, and the fetus 
Table 3
Maternal and fetal morbidity associated with gestational diabetes mellitus. 
Maternal morbidity Fetal/neonatal/child morbidity
Early pregnancy Stillbirth
   Spontaneous abortions Neonatal death
Pregnancy Nonchromosomal congenital malformations
   Pre-eclampsia Shoulder dystocia
   Gestational hypertension Respiratory distress syndrome
   Excessive fetal growth (macrosomia, large for gestational age) Cardiomyopathy
   Hydramnios Neonatal hypoglycemia
   Urinary tract infections Neonatal polycythemia
Delivery Neonatal hyperbilirubinemia
   Preterm labor Neonatal hypocalcemia
   Traumatic labor Erb’s palsy (as consequence of birth injury)
   Instrumental delivery Programming and imprinting; fetal origins of disease: diabetes, obesity, hypertension, 
metabolic syndrome   Cesarean delivery
   Postoperative/postpartum infection
   Postoperative/postpartum hemorrhage
   Thromboembolism
   Maternal morbidity and mortality
   Hemorrhage
Puerperium
   Failure to initiate and/or maintain breastfeeding
   Infection
Long-term postpartum
   Weight retention
   GDM in subsequent pregnancy
   Future overt diabetes
   Future cardiovascular disease
Maternal excess circulang 
glucose, lipids, amino acids 
Fetal substrates transfer 
Fetal hyperinsulinemia 
Fetal substrate uptake 
MacrosomiaTissue oxygen consumpon Lung surfactant 
synthesis 










Figure 3 Intrauterine exposure to maternal hyperglycemia: Fetal and neonatal complications in the short term. Adapted and republished with permission from Elsevier, 
from: Mitanchez D, Yzydorczyk C, Siddeek B, Boubred F, Benahmed M, Simeoni U. The offspring of the diabetic mother--short- and long-term implications. Best Pract Res 
Clin Obstet Gynaecol 2015;29(2):256–69.
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is totally dependent on transfer of nutrients from the maternal 
circulation via the placenta. As early as 1954, Pedersen et al. 
[26] demonstrated that newborns of diabetic mothers suffered 
from hypoglycemia and hypothesized that this was due to fetal 
hyperinsulinism as a result of increased transplacental transfer 
of sugar. Van Assche and Gepts [27] later confirmed the presence 
of hyperplasia of the insulin-producing beta cells in infants of 
diabetic mothers and postulated that the hyperplasia was related 
to beta-cell hyperactivity and could have consequences in later 
life.
In animal experiments, Aerts and Van Assche [28] showed 
that modifications in the endocrine pancreas during intrauterine 
life caused persistent changes that manifest in later adult life 
(in the second generation). Though not perceptible under 
basal conditions, these changes become apparent in situations 
stressing the beta cell activity, such as pregnancy. Pregnancy 
in second generation rats showed increased nonfasting blood 
glucose, with no apparent adaptation of the beta cells. This 
inadequate adaptation to pregnancy caused changes in the fetal 
endocrine pancreas in fetuses of the third generation, thereby 
suggesting a transgenerational transmission of risk.
It is now evident that an abnormal intrauterine environment has 
consequences in later life mediated through epigenetic changes. 
This phenomenon is known as developmental programming. An 
increasing body of evidence supports the hypothesis that the 
abnormal metabolic environment of the mother with diabetes 
mellitus may affect certain developing fetal tissues, organs, and 
control systems, eventually leading to permanent long-term 
functional implications in adult life. The fetal tissues most likely 
to be affected are neural cells, adipocytes, muscle cells, and 
pancreatic beta cells. Freinkel [29] introduced the concept of 
pregnancy as a “tissue culture experiment,” in which the placenta 
and the fetus develop in an “incubating medium” totally derived 
from maternal fuels. All these fuels traverse the placenta from 
the maternal compartment either with (e.g. glucose, lipids) or 
against (e.g. amino acids) concentration gradients and contribute 
to the fetal milieu. Since these constituents are regulated, in 
part, by maternal insulin, disturbances in its supply or action 
influence the nutritional environment to which the fetus is 
exposed; maternal hyperglycemia leads to fetal hyperglycemia 
and eventually to fetal hyperinsulinemia.
According to Freinkel’s hypothesis, the abnormal mixture 
of metabolites from the mother gains access to the developing 
fetus in utero, modifying the phenotypic expression in newly 
formed cells, which in turn determine permanent, short- and 
long-term effects in the offspring. Depending upon the timing of 
(embryonic–fetal) exposure to the aberrant fuel mixture, different 
events may develop. Early in the first trimester, intrauterine 
growth restriction and organ malformation, described by 
Freinkel as “fuel-mediated teratogenesis” may occur. During 
the second trimester, at the time of brain development and 
differentiation, behavioral, intellectual, or psychological damage 
may occur. During the third trimester, abnormal proliferation 
of fetal adipocytes and muscle cells, together with hyperplasia 
of pancreatic beta cells and neuroendocrine cells may be 
responsible for the development of obesity, hypertension, and 
T2DM mellitus later in life.
4.10. Maternal implications
Until the discovery of insulin by Banting and Best in 1921, very 
few women with diabetes based on severe insulin deficiency 
became pregnant spontaneously, and even fewer achieved 
a successful pregnancy outcome. At that time, about 50% of 
such women died during pregnancy from diabetes-related 
complications (mainly ketoacidosis) and about 50% of the fetuses 
failed to develop in utero. Women with diabetes mellitus had a 
markedly higher risk of poor pregnancy outcome, as described 
earlier. These complications, together with the increased rate of 
vascular dysfunction (retinopathy and nephropathy), contributed 
to higher maternal morbidity and mortality among patients 
with diabetes mellitus. Moreover, hyperglycemia first appearing 
during pregnancy was associated with a high risk of developing 
diabetes and cardiovascular diseases in later life [30–34].
Currently, pregnant women with diabetes mellitus enjoy the 
benefits of extraordinary progress made in all areas of medicine 
and in obstetrics in particular. State-of-the-art tools have been 
developed for diagnosis, treatment, and follow-up of both mother 
and fetus, such as fetal heart rate monitors, ultrasonography, 
glucose self-monitors, and insulin pumps. As a result, leading 
medical centers worldwide report a major reduction in maternal 
and fetal complications of diabetic pregnancies reaching levels 
similar to those in normal pregnancy. Clinicians working in these 
centers recognize unequivocally that early diagnosis, adequate 
treatment, and close follow-up are essential to decrease the 
incidence of most complications of diabetes in pregnancy and to 
achieve a successful outcome.
Despite these developments, the majority of women in 
low-, lower middle-, and upper middle-resource countries 
(contributing to over 85% of global deliveries annually), are not 
properly screened for diabetes during pregnancy. These countries 
also account for 80% of the global burden of diabetes as well as 
90% of the global burden of maternal and perinatal deaths and 
poor pregnancy outcomes.
Maternal vulnerability to future diabetes and cardiovascular 
disorders is rising. Given the interaction between hyperglycemia 
and poor pregnancy outcomes and the role of the in utero 
environment in increasing risk of diabetes and cardiometabolic 
disorders in offspring of mothers with hyperglycemia in 
pregnancy, there needs to be a greater focus on preventing, 
screening, diagnosing, and managing hyperglycemia in 
pregnancy, globally, but particularly in low-resource countries.
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5.1. Problems of multiple criteria
Global healthcare organizations and professional bodies have 
advocated a plethora of diverse algorithms for screening and 
diagnosis of GDM. Unfortunately, even the endocrine, diabetes, 
and obstetric associations within particular countries often used 
markedly dissimilar protocols and cut-off values for screening 
and diagnosis of GDM. These recommendations for GDM were 
criticized for lacking validation, as they were developed based 
on tenuous data, the result of expert opinions, were biased 
owing to economic considerations, or convenience-oriented 
[1], thereby creating confusion and uncertainty among care 
providers. One underlying yet fundamental problem, as shown 
consistently by several studies including the Hyperglycemia 
and Adverse Pregnancy Outcomes (HAPO) study, is that the risk 
of poor pregnancy outcomes associated with hyperglycemia is 
continuous with no clear inflection points [2–6].
It is therefore clear that any set of criteria for the diagnosis 
of GDM proposed will need to evolve from a consensus 
approach, balancing risks and benefits in particular social, 
economic, and clinical contexts [7]. In 2010, International 
Association of Diabetes in Pregnancy Study Groups (IADPSG) 
proposed consensus derived cut-off values for fasting, 1-hour, 
and 2-hour 75-g OGTT threshold values, defining GDM based 
on odds ratio thresholds of 1.75 in comparison with the mean, 
for markers of diabetic fetopathy (LGA, excess fetal adiposity, 
and fetal hyperinsulinemia) in the multinational observational 
HAPO study [8]. These criteria have been widely accepted 
and recently adopted by the WHO and the American Diabetes 
Association (ADA) [9,10]. However, LGA and fetal adiposity 
are also dependent on factors other than maternal glucose 
alone. For example, using the 2-hour glucose cut-off value of 
8.5 mmol/L (153 mg/dL) selected by the IADPSG may not be 
as efficient in identifying women at-risk for fetal overgrowth 
as those identified by a 2-hour glucose value corresponding 
to that at a slightly lower odds ratio of 1.5 compared with the 
mean. The latter corresponds to the older, WHO criteria 2-hour 
value of 7.8 mmol/L (140 mg/dL).
Apart from the different cut-off values, the lack of consensus 
among the different professional bodies for an algorithm for 
screening and diagnosis of GDM is perhaps an even larger problem. 
Despite repeated pleas for a single process and criteria [11], the 
ideal protocol for the diagnosis of GDM continues to be debated.
5.2. Universal versus selective testing
Selective testing based on clinical risk factors for GDM 
evolved from the view that in populations with a low risk of 
GDM, subjecting all pregnant women to a laboratory test was 
not considered cost-effective. Traditionally, the risk factor-based 
approach was popular in Europe. Some of the aforementioned 
risk factors used were: age and BMI (at varying thresholds); 
ethnicity; polyhydramnios; macrosomia (current or past preg-
nancy); GDM in the past; unexplained stillbirth; T2DM in a first-
degree relative; and PCOS. The Toronto Tri-hospital Gestational 
Diabetes Project [12] developed a scoring system based on 
maternal age, BMI, and race. However, variations in risk factors 
have resulted in different approaches, generally with poor 
sensitivity and specificity. The major problem of risk factor-
based screening is its high demand on the healthcare providers 
with more complex protocols for testing, which result in lower 
compliance by both patients and healthcare providers.
Given the high rates of hyperglycemia in pregnancy in 
most populations and that selective testing based on known 
risk factors has poor sensitivity for detection of GDM, it seems 
appropriate to recommend universal rather than risk factor-
based testing. This approach is strongly recommended by FIGO 
and is particularly relevant to low-, low−middle, and middle-
resource countries, where 90% of all cases of GDM are found 
and ascertainment of risk factors is poor owing to low levels of 
education and awareness, and poor record keeping. In many of 
these countries there is little justification for selective testing, as 
they also have ethnic populations considered to be at high risk 
[13].
In 2010 the IADPSG proposed screening of all pregnant women 
with a single step 75-g OGTT [8]. This position has since been 
supported by the ADA and the IDF (2014) [14]. However, there 
continues to be a lack of uniformity of testing protocols within 
and between hospitals in the same city, county, and country [15], 
let alone internationally.
The case for universal testing (i.e. testing all pregnant women) 
with some biochemical test has its supporters [16,17]. However, 
even among advocates of universal testing there is a lack of 
uniformity in approach to testing methodology.
(1) The 50-g glucose challenge test (GCT) has been the most 
popular test for this purpose. This is part of the two-
step algorithm (50-g GCT followed by the 100-g OGTT) 
still advocated by ACOG and offered as an alternative 
diagnostic strategy in the latest ADA guideline.
(2) The 1-step 75-g OGTT in all women is endorsed by the 
WHO, IDF, and many other organizations that agree with 
the recommendations of the IADPSG.
In the overall cost of providing care to women with GDM 
the cost of administering a glucose tolerance test (GTT) to all 
pregnant women is likely to be minimal if the initial fasting GTT 
level result can be used to decide if the full GTT is needed [18,19]. 
In situations where women may not be able to come for testing 
in a fasting state, a single step 75-g 2-hour nonfasting test, as 
used in India, may be applied [20,21].
The FIGO initiative for GDM is meant to provide a practical 
guide for national associations to adopt and promote a uniform 
approach to testing, diagnosis, and management of GDM for 
all countries and regions based on their financial, human, and 
infrastructure resources.
5.3. Diagnostic criteria
5.3.1. Diabetes in pregnancy
The diagnosis of diabetes in pregnancy as defined by the 
WHO criteria [9] should be based on one or more of the following 
results recorded by routine testing at any time during the course 
of pregnancy:
(1) Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL); and/or
(2) 2-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) 
following a 75-g oral glucose load; or
(3) Random plasma glucose ≥11.1 mmol/L (200 mg/dL) in the 
presence of diabetes symptoms.
5. Diagnosing gestational diabetes mellitus
• FIGO adopts and supports the IADPSG/WHO/IDF position 
that all pregnant women should be tested for hyperglycemia 
during pregnancy using a one-step procedure.
• FIGO encourages all countries and its member associations 
to adapt and promote strategies to ensure universal 
testing of all pregnant women for hyperglycemia during 
pregnancy.
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Additionally, the ADA also recommends HbA1c (≥6.5%), 
confirmed by repeat testing, as sufficient to diagnose diabetes in 
the presence or absence of pregnancy [10].
5.3.2. Gestational diabetes mellitus
As per the recommendation of the IADPSG (2010) and WHO 
(2013), the diagnosis of GDM is made using a single-step 75-g 
OGTT when one or more of the following results are recorded 
during routine testing specifically between weeks 24 and 28 of 
pregnancy or at any other time during the course of pregnancy:
(1) Fasting plasma glucose 5.1−6.9 mmol/L (92−125 mg/dL);
(2) 1-hour post 75-g oral glucose load ≥10 mmol/L (180 mg/dL);
(3) 2-hour post 75-g oral glucose load 8.5–11.0 mmol/L 
(153−199 mg/dL)
FIGO suggests various options for diagnosis of GDM based on 
resource settings in Table 4.
5.3.3. Resource-based approach to diagnosis
Implementation of guidelines is a constant challenge. The 
reality is that most low-resource countries around the world 
are unable to implement a GDM detection program based on a 
universal 75-g OGTT or rely on just high-risk women undergoing 
a 75-g OGTT. These challenges and barriers have been reviewed 
extensively [28]. The applicability of the IADPSG cut-off value for 
fasting glucose to diagnose GDM, especially in the first trimester 
has been contested in a recent study from China [29].
Recommendations that are rigid and impractical in real-life 
settings are unlikely to be implemented and hence may produce 
little or no impact. On the other hand, pragmatic but less than 
ideal recommendations may produce significant impact owing 
to more widespread implementation.
The FIGO approach is three pronged: (1) to promote, 
encourage, and advocate ideal evidence-based guidance; 
(2) to offer pragmatic options for resource-constrained 
situations based on local experience backed by less than 
optimal evidence; and (3) to promote research aimed at 
improving the evidence base in both well-resourced and 
resource-constrained contexts.
FIGO recommendations are based on available resources at 
country level and evidence of local practice. Countries worldwide 
fall into four resource categories. There are also variations seen 
within any country. An affluent country may have pockets of 
poorly funded care and conversely, a low- or middle-resource 
country may have state-of-the art care in the private sector for 
a selected few.
High-resource countries: countries or regions such as Canada, 
Western Europe, Japan, South Korea, USA, etc.
Upper middle-resource countries: countries such as Brazil, 
China, Colombia, Hungary, Malaysia, Mexico, Romania, South 
Africa, Turkey, etc.
Low middle-resource countries: countries such as India, 
Indonesia, Pakistan, Nigeria, Egypt, Vietnam, etc.
Low-resource countries: countries such as Bangladesh, Nepal, 
Cambodia, Kenya, Tanzania, Uganda, Ethiopia, Congo, etc.
5.3.4. Risk models
If a country cannot afford any laboratory testing, risk models 
are available. Many have been advocated from studies in Canada 
[12], Denmark [30], Thailand [31], and Vietnam [32]. They use a 
permutation of various clinical risk factors, including age, BMI, 
family history of diabetes mellitus, GDM in past pregnancies, 
LGA newborns, and glycosuria. Their widespread applicability in 
large settings in low-resource countries has not been tested and 
is not recommended by FIGO.
Eight low- and middle-resource countries—India, China, 
Nigeria, Pakistan, Indonesia, Bangladesh, Brazil, and Mexico—
account for 55% of the global live births (70 million live births 
annually) as well as 55% of the global burden of diabetes (209.5 
million) and should be key targets for any focused strategy on 
addressing the global burden of GDM pregnancies.
A few examples of current approaches to diagnoses of GDM 
in different parts of the world, particularly from the large 
burden countries where systematic testing for GDM is being 
implemented, are provided in Appendix 1. These examples have 
inspired FIGO’s pragmatic options and guidance for resource-
constrained situations.
5.4. Cost-effectiveness of GDM testing and management
Apart from infrastructure and capacity constraints, imple-
mentation of universal testing for GDM is challenged by lack of 
good evidence to support cost-effectiveness in both the high- and 
low-resource countries. To facilitate decision-making, countries 
need reliable information on the cost and cost-effectiveness of 
GDM screening and treatment. Almost all cost-effectiveness 
analyses have assessed only short-term complications [33], 
omitting consideration of reductions in long-term T2DM. A recent 
study from the USA evaluated the potential cost-effectiveness of 
new GDM screening criteria for both time periods [34]. Another 
study, based on the Gestational Diabetes Formulas for Cost-
Effectiveness or GeDiForCE Model [35] described in Appendix 2, 
showed that the interventions are “highly cost-effective” in both 
Indian and Israeli settings when long-term effects are taken into 
account [36].
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Table 4
Options for diagnosis of gestational diabetes mellitus based on resource settings.
Strategy
Setting Who to test and when Diagnostic test Interpretationa Grade
Fully resourced settings All women at booking/first 
trimester
24−28 weeks
Measure FPG, RBG, or HbA1c to detect 
diabetes in pregnancy
If negative: perform 75-g 2-hour OGTT 
1|
Fully resourced 
settings serving ethnic 
populations at high 
riskb
All women at booking/first 
trimester
24−28 weeks
Perform 75-g 2-hour OGTT to detect 
diabetes in pregnancy
If negative: perform 75-g 2-hour OGTT
2|
Any setting (basic); 
particularly medium- 
to low-resource 
settings serving ethnic 
populations at risk 
All women between 24 and 28 
weeks
Perform 75-g 2-hour OGTT 1|




serving populations at 
high risk
All women at booking/first 
trimester
24−28 weeks
Measure FPG to detect diabetes in 
pregnancy
If negative: perform 75-g 2-hour OGTT
Or
To reduce number of OGTTs measure FPG.
Only in women with values between 
4.5 mmol/L and 5.0 mmol/L (81−90 mg/dL) 
perform 75-g 2-hour OGTT
>7.0 mmol/L or >126 mg/dL.   FPG 
values between 5.6 and 6.9 mmol/L, 
(100−125 mg/dL) consider as GDM 
[18]










populations at high risk
All women at booking/first 
trimester
24−28 weeks
Measure fasting or nonfasting 2-hour value 
after 75-g OGTT
If negative: repeat test 
Reading between 7.8 and 11.0 mmol/L 






All women at booking/first 
trimester
24−28 weeks
Measure FPG to detect diabetes in 
pregnancy
If negative: perform 75-g 2-hour OGTT 
>7.0 mmol/L or >126 mg/dL.
FPG values between 5.6 and 
6.9 mmol/L (100−125 mg/dL), 
consider as GDM
75-g 2-hour glucose value 





Selected women at booking/as 
soon as possiblee
24−28 weeks
Offered also to other women with 
risk factors for GDMf
Perform 75-g 2-hour OGTT
If negative: perform 75-g 2-hour OGTT
FPG of 5.6 mmol/L or above or 2-hour 
plasma glucose of 7.8 mmol/L or 
above is diagnosticg
Abbreviations: FPG, fasting plasma glucose; RBG, random blood glucose; HbA1c, glycosylated hemoglobin; GDM, gestational diabetes mellitus; OGTT, oral 
glucose tolerance test.
a Interpret as per IADPSG/WHO/IDF guidelines unless stated otherwise.
b Asians are at high risk of hyperglycemia during pregnancy, which may include previously undiagnosed diabetes. The proportion of previously undiagnosed 
diabetes is highest in the youngest age group particularly among women [22]. In Asian populations, FPG and HbA1c have much lower sensitivity to 
diagnose diabetes than the 2-hour post-glucose value [23]. In a study of 11 Asian cohorts, more than half of the diabetic subjects had isolated postchallenge 
hyperglycemia [24]. In a study in China, 46.6% of the participants with undiagnosed diabetes (44.1% of the men and 50.2% of the women) had isolated 
increased 2-hour plasma glucose levels after an OGTT [25]. Therefore, the need to identify postprandial hyperglycemia seems especially relevant in Asian 
populations.
c Diabetes in Pregnancy Study Group in India (DIPSI) Guideline [8].
d Latin America Study Group [26].
e Women with a past history of GDM or women with glycosuria of 2+ or above on one occasion or of 1+ or above on two or more occasions (as detected by 
reagent strip testing during routine prenatal care in the current pregnancy).
f BMI above 30 (calculated as weight in kilograms divided by height in meters squared), previous macrosomic baby weighing 4.5 kg or above, family history of 
diabetes, first-degree relative with diabetes, minority ethnic family origin with a high prevalence of diabetes.
g National Institute for Health and Care Excellence (NICE) [27].
 M. Hod et al. / International Journal of Gynecology and Obstetrics 131 S3 (2015) S173–S211 S187
glucose tolerance test and adverse pregnancy outcomes. Diabetes Care 
2001;24(7):1151–5.
 [7] McIntyre HD, Colagiuri S, Roglic G, Hod M. Diagnosis of GDM: a suggested 
consensus. Best Pract Res Clin Obstet Gynaecol 2015;29(2):194–205.
 [8] International Association of Diabetes and Pregnancy Study Groups 
Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano 
PA, et al. International association of diabetes and pregnancy study groups 
recommendations on the diagnosis and classification of hyperglycemia in 
pregnancy. Diabetes Care 2010;33(3):676–82.
 [9] World Health Organization. Diagnostic Criteria and Classification of 
Hyperglycaemia First Detected in Pregnancy. http://apps.who.int/iris/bit-
stream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf. Published 2013.
 [10] American Diabetes Association. Standards of Medical Care in Diabetes 
-Classification and Diagnosis of Diabetes. Diabetes Care 2015;38(Suppl 
1);S8–S16.
 [11] Sacks DB. Diagnosis of gestational diabetes mellitus: it is time for interna-
tional consensus. Clin Chem 2014;60(1):141–3.
 [12] Naylor CD, Sermer M, Chen E, Farine D. Selective screening for gestational dia-
betes mellitus. Toronto Trihospital Gestational Diabetes Project Investigators. 
N Engl J Med 1997;337(22):1591–6.
 [13] Neilsen KK, De Courten M, Kapur A. The urgent need for universally appli-
cable simple screening procedures and diagnostic criteria for gestational 
diabetes mellitus - lessons from projects funded by the World Diabetes 
Foundation. Glob Health Action 2012;5:17277.
 [14] Colagiuri S, Falavigna M, Agarwal MM, Boulvain M, Coetzee E, Hod M, et 
al. Strategies for implementing the WHO diagnostic criteria and classifica-
tion of hyperglycaemia first detected in pregnancy. Diabetes Res Clin Pract 
2014;103(3):364–72.
 [15] Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes 
mellitus: results from a survey of country prevalence and practices. J Matern 
Fetal Neonatal Med 2012;25(6):600–10.
 [16] Moses RG, Cheung NW. Point: Universal screening for gestational diabetes 
mellitus. Diabetes Care 2009;32(7):1349–51.
 [17] Simmons D, Moses RG. Gestational diabetes mellitus: to screen or not to 
screen?: Is this really still a question? Diabetes Care 2013;36(10):2877–8.
 [18] Agarwal MM, Dhatt GS, Shah SM. Gestational diabetes mellitus: simplifying 
the international association of diabetes and pregnancy diagnostic algorithm 
using fasting plasma glucose. Diabetes Care 2010;33(9):2018–20.
 [19] Zhu WW, Fan L, Yang HX, Kong LY, Su SP, Wang ZL, et al. Fasting plasma glu-
cose at 24-28 weeks to screen for gestational diabetes mellitus: new evi-
dence from China. Diabetes Care. 2013 Jul;36(7):2038−40.
 [20] Anjalakshi C, Balaji V, Balaji MS, Ashalata S, Suganthi S, Arthi T, et al. A sin-
gle test procedure to diagnose gestational diabetes mellitus. Acta Diabetol 
2009;46(1):51–4.
 [21] Seshiah V, Balaji V, Shah SN, Joshi S, Das AK, Sahay BK, et al. Diagnosis of 
gestational diabetes mellitus in the community. J Assoc Physicians India 
2012;60:15–7.
 [22] Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-Johnsen K, et al. Age- 
and sex-specific prevalence of diabetes and impaired glucose regulation in 11 
Asian cohorts. Diabetes Care 2003;26(6):1770–80.
 [23] Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 
2010;375(9712):408–18.
 [24] Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, et 
al. Comparison of the fasting and the 2-h glucose criteria for diabetes in dif-
ferent Asian cohorts. Diabetologia 2000;43(12):1470–5.
 [25] Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among 
men and women in China. N Engl J Med 2010;362(12):1090–101.
 [26] de Sereday MS, Damiano MM, González CD, Bennett PH. Diagnostic crite-
ria for gestational diabetes in relation to pregnancy outcome. J Diabetes 
Complications 2003;17(3):115–9.
 [27] National Institute for Health and Care Excellence (NICE). Diabetes in preg-
nancy: management of diabetes and its complications from preconception to 
the postnatal period. NICE guidelines [NG3]. http://www.nice.org.uk/guid-
ance/ng3/evidence. Published February 2015.
 [28] Nielsen KK, Kapur A, Damm P, de Courten M, Bygbjerg IC. From screening to 
postpartum follow-up - the determinants and barriers for gestational diabe-
tes mellitus (GDM) services, a systematic review. BMC Pregnancy Childbirth 
2014;14:41.
 [29] Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al. Evaluation of the 
value of fasting plasma glucose in the first prenatal visit to diagnose gesta-
tional diabetes mellitus in China. Diabetes Care 2013;36(3):586–90.
 [30] Jensen DM, Mølsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, 
Damm P. Screening for gestational diabetes mellitus by a model based on risk 
indicators: a prospective study. Am J Obstet Gynecol 2003;189(5):1383–8.
 [31] Phaloprakarn C, Tangjitgamol S, Manusirivithaya S. A risk score for selective 
screening for gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol 
2009;145(1):71–5.
 [32] Tran TS, Hirst JE, Do MA, Morris JM, Jeffery HE. Early prediction of gestational 
diabetes mellitus in Vietnam: clinical impact of currently recommended 
diagnostic criteria. Diabetes Care 2013;36(3):618–24.
 [33] Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Cost-effectiveness 
analysis of gestational diabetes mellitus screening in France. Eur J Obstet 
Gynecol Reprod Biol 2002;103(2):122–9.
 [34] Werner EF, Pettker CM, Zuckerwise L, Reel M, Funai EF, Henderson J, et al. 
Screening for gestational diabetes mellitus: are the criteria proposed by the 
international association of the Diabetes and Pregnancy Study Groups cost-
effective? Diabetes Care 2012;35(3):529–35.
 [35] Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-
effectiveness of gestational diabetes mellitus screening and lifestyle change 
for the prevention of type 2 diabetes mellitus. Int J Gynecol Obstet 2011;115 
Suppl 1:S20–5.
 [36] Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al . The cost-
effectiveness of gestational diabetes screening including prevention of type 
2 diabetes: application of a new model in India and Israel. J Matern Fetal 
Neonatal Med 2013;26(8):802–10.
S188 M. Hod et al. / International Journal of Gynecology and Obstetrics 131 S3 (2015) S173–S211 
Glucose levels are generally measured from serum, plasma, or 
whole blood. Today, most glucose measurements in laboratories 
are performed on serum or plasma. The glucose concentration 
in whole blood is approximately 15% lower than the glucose 
concentration in serum or plasma. Serum or plasma must be 
refrigerated and separated from the cells quickly to prevent 
substantial metabolism of glucose by the cellular fraction. The 
requirement that serum samples must be allowed to clot before 
serum glucose is tested significantly increases turnaround time 
for glucose results compared with plasma results. Thus, faster 
laboratory turnaround time is one reason that plasma has 
become the gold standard for glucose measurement. However, 
in most laboratory panels (i.e. the comprehensive metabolic 
panel), serum is the most suitable sample for all other laboratory 
tests performed, and so a “panel” glucose is usually a serum 
glucose. If plasma is used, the rapid separation of the red blood 
cells from the plasma by centrifugation is a critical element, 
because it is estimated that plasma glucose levels are reduced by 
approximately 10 mg/dL per hour by consumption of glucose in 
the red blood cell’s glycolytic pathway.
Previously, sodium fluoride (gray-top tubes) was often used 
as an anticoagulant and preservative of whole blood, particularly 
when analysis was delayed. A recent study showed that citrate 
buffer inhibited in vitro glycolysis far more effectively than 
fluoride [1]. Lately, citrate buffer has been advocated as a rapidly 
effective glycolysis inhibitor. The mean glucose concentration in 
samples stored at 37°C decreased by only 0.3% at 2 hours and 
1.2% at 24 hours when blood was drawn into tubes containing 
citrate buffer, sodium fluoride, and ethylenediaminetetraacetic 
acid (EDTA). The use of these blood collection tubes appears to 
offer a practical solution to the glycolysis problem [2]. Plasma 
from blood collected in fluoride tubes is generally unsuitable for 
measuring other laboratory parameters.
Glucose levels also vary depending on the source of the 
blood sample used for analysis, i.e. arterial, capillary, or venous. 
The variation is attributed to variation in glucose extraction 
by tissues, perfusion, oxygenation, pH, and temperature. On 
average, arterial glucose concentrations at normal partial 
pressure of oxygen are 5 mg/dL higher than capillary blood and 
approximately 10 mg/dL greater than venous concentrations. 
Except in intensive care situations plasma glucose is normally 
measured from venous or capillary blood.
Glucose measurements are based on enzymatic reactions 
involving one of the four enzymes: glucose oxidase (GO), glucose 
1-dehydrogenase (GD), glucokinase (GK), or hexokinase (HK). 
The most widely used methods of glucose analysis use the 
enzymes GO, GK, or HK. GO is the most specific enzyme reacting 
only with D-glucose. The GK or HK method is considered more 
accurate than the GO method.
For point-of-care devices, GO or GD are the classic methodolo-
gies. GK and HK are the basis for many central laboratory methods.
Additional variability in glucose measurement may occur 
because of differences in different assays, collection and storage 
of samples, and quality of reagents (storage of test strips) etc.
Point-of-care blood glucose measurement is based on 
capillary whole blood, while laboratory-based measurements 
are usually based on venous plasma.
6.1. Laboratory testing
An array of instruments, from the simplest to the most 
sophisticated, are capable of measuring plasma glucose. Ideally, 
only accredited laboratories should be allowed to report any 
patients’ results, since they account for major medical decisions. 
The minimum quality specifications are documented by accrediting 
bodies such as the College of American Pathologists (CAP) and 
the International Organization for Standards (ISO) 15189, etc.
Due to constraints of resources or available expertise, more 
often than not, results are reported by unaccredited laboratories. 
However, even low-resource countries can produce excellent 
laboratory results; conversely an overabundance of resources 
does not guarantee good quality. What is required is meticulous 
application of procedures. It is obligatory that every laboratory 
meticulously document: (1) reproducibility (precision) by re cord-
ing internal quality control daily and calculating the Coefficient 
of Variation (CV%) monthly; and (2) accuracy (bias) by comparing 
its results through proficiency testing or comparing its results 
to an accredited laboratory. Once minimum requirements of 
precision are met by good laboratory practices, the bias can be 
addressed. For plasma glucose, the imprecision should be less 
than 2.9%, the accuracy (bias) less than 2.2%, and a total error less 
than 6.9%, based on biological variation of glucose [3].
6.2. Near patient or point-of-care testing
Ideally, the results of handheld glucose meters should match 
those of laboratory analyzers of an accredited laboratory. 
Furthermore, the targets for screening of diabetes, self-
monitoring of glucose, and acute hospital critical care settings 
are not the same.
No universal criteria for the analytical performance of glucose 
meters exist. Generally, the performance of the glucometer is 
considered satisfactory if 95% of glucometer values fall within 
a specified percentage of simultaneously measured patient 
plasma glucose on laboratory analyzers. Current glucometer 
recommendations (compared with laboratory methods) range 
widely from ±5% to ±20% [3]. In January 2014, the US Food and 
Drug Administration recommended quality requirements; 
however, they are too stringent and have thus been criticized by 
most professional bodies [4].
When using a glucometer it is important to know what value is 
being reported, i.e. whether it is whole blood or plasma-correlated 
glucose. “Plasma correlated” refers to glucose concentrations 
measured in samples of whole blood but are converted to values 
that would be expected of plasma measurements. The site of 
blood collection may create additional variability. In general, 
blood samples for glucometer reading should be collected 
from the fingertips. The technique of glucometer use is usually 
responsible for more inaccuracy than the glucometer itself. 
Technical errors result from improper calibration and inadequate 
maintenance, in addition to the specific techniques used to 
measure glucose: photometric versus electrochemical, as well as 
the type of enzyme used (HK vs GO vs GD) [5].
Ideally, for diagnosis of GDM, reliable test results should 
be based on venous plasma samples properly collected and 
transported prior to laboratory testing. However, this ideal 
situation may not be present in many primary care settings, 
particularly in low-income countries where proper facilities 
for collection, transport, storage or testing may not exist. In 
this situation FIGO recommends that it is acceptable to use a 
plasma calibrated hand held glucometer with properly stored 
test strips to measure plasma glucose. Regular calibration 
should be undertaken with standard test solutions (usually 
supplied by the glucose meter manufacturer). Using a glucose 
6. Glucose measurement: Technical considerations in laboratory and 
point-of-care testing
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meter in this situation may be more reliable than laboratory 
tests done on samples that have been inadequately handled 
and transported.
References
 [1] Gambino R, Piscitelli J, Ackattupathil TA, Theriault JL, Andrin RD, Sanfilippo 
ML, et al. Acidification of blood is superior to sodium fluoride alone as an 
inhibitor of glycolysis. Clin Chem 2009;55(5):1019–21.
 [2] Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. 
Guidelines and recommendations for laboratory analysis in the diagnosis 
and management of diabetes mellitus. Diabetes Care 2011;34(6):e61–99.
 [3] Sacks DB, ed. Guidelines and Recommendations for Laboratory Analysis in the 
Diagnosis and Management of Diabetes Mellitus. https://www.aacc.org/~/
media/practice-guidelines/diabetes-mellitus/diabetesmellitusentirelmpg.
pdf?la=en. Published 2011.
 [4] Polen M. AACC urges New York State to rescind policy directive that could nega-
tively impact patients by restricting the use of blood glucose meters. American 
Association for Clinical Chemistry; June 17, 2014. https://www.aacc.org/media/
press-release-archive/2014/aacc-urges-new-york-state-to-rescind-policy-directive
 [5] Schrot RJ, Patel KT, Foulis P. Evaluation of inaccuracies in the measurement of 
glycemia in the laboratory, by glucose meters, and through measurement of 
hemoglobin A1c. Clinical Diabetes 2007;25(2):43–49.
• GDM diagnosis should be ideally based on blood tests 
done in an accredited laboratory on properly collected and 
transported venous plasma samples.
• FIGO recommends the use of a plasma-calibrated handheld 
glucometer with properly stored test strips to measure 
plasma glucose in primary care settings, particularly in 
low-resource countries, where a close-by laboratory or 
facilities for proper storage and transport of blood samples 
to a distant laboratory may not exist. This may be more 
convenient and reliable than tests done on inadequately 
handled and transported blood samples in a laboratory. It 
is recommended that from time to time a few samples are 
parallel tested in an accredited laboratory to document the 
variability.
• FIGO recommends that all laboratories and clinical 
services document their baseline quality and work toward 
improvement irrespective of the resources available.
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Fetal and maternal outcomes are directly correlated with 
the degree of maternal glycemic control. The primary goal of 
treatment for pregnancies complicated by diabetes is to ensure 
as close to normal outcome as possible for the mother and 
offspring by controlling maternal hyperglycemia.
7.1. Prenatal supervision
There is no evidence to support a particular protocol of 
prenatal care and monitoring for women with diabetes. The 
recommendations in Box 1 are based on the ACOG practice 
bulletin [1], as well as consensus on clinical practice.
7.1.1. Fetal sonographic assessment
Monitoring fetal growth is both challenging and inaccurate, 
with a ±15% error margin. Since fetal macrosomia is the most 
frequent complication of diabetes, special effort should be 
directed toward its diagnosis and prevention. Recommendations 
for fetal growth assessment are shown in Box 2.
7.1.2. Fetal well-being
Fetal assessment can be achieved by a fetal kick count, 
biophysical profile, and cardiotocography (nonstress test). 
There is no high-quality evidence to support a particular follow-
up protocol. However, it is assumed that with reassuring fetal 
well-being, pregnancy prolongation to term can be achieved [1]. 
Recommendations for assessment of fetal well-being are shown 
in Box 3.
7.1.3. Timing and mode of delivery
Maternal hyperglycemia and macrosomia are associated 
with increased risk of intrauterine fetal death and other adverse 
outcomes. Therefore, induction of labor may be considered 
at 38−39 weeks, although there is no good-quality evidence 
to support such an approach. Thus, some guidelines suggest 
that a pregnancy with good glycemic control and a seemingly 
appropriate estimated weight for gestational age fetus ought 
to continue until 40−41 weeks [2–4]. Given the significantly 
greater risk of shoulder dystocia at any birthweight above 3750 
g for babies of women with diabetes, consideration may be given 
to elective cesarean delivery when the best estimate of fetal 
weight exceeds 4000 g [5–10] (Figure 4). Recommendations for 
timing and mode of delivery in women with GDM are shown 
in Box 4.
7. Management of hyperglycemia during pregnancy
• FIGO recognizes that management of diabetes in pregnancy 
should be made in accord with available national resources 
and infrastructure, even without high-quality evidence, as 
it is preferable to the alternative of no or poor care.
Box 1
Recommendations for prenatal supervision in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Routine prenatal care should include visits to:
• Healthcare professionals skilled in care of women with diabetes in pregnancy 
(obstetrician, perinatologist, diabetologist, diabetes educator, nutritionist etc): 
1−3 weeks as needed
• Nurse: Weight, blood pressure, dipstick urine protein: 1-2 weeks as needed 
High 1|
Prenatal follow-up determined locally according to available resource:
• A minimum of monthly check-ups with a healthcare provider knowledgeable 
in diabetes in pregnancy 
Mid and Low 2|
Box 2
Recommendations for fetal growth assessment in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Clinical and sonographic growth assessments every 2−4 weeks from diagnosis 
until term 
High 1|
Periodic clinical and sonographic growth assessments from diagnosis until term Mid and Low 2|
Box 3
Recommendations for fetal well-being surveillance in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Use cardiotocography and/or biophysical profi le or kick-count as indicated 
according to local protocol
All 1|
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7.2. Glucose measurements
Blood glucose control can be evaluated in one of three ways: 
glycosylated hemoglobin (HbA1c), self-monitoring of blood 
glucose, or continuous glucose monitoring.
7.2.1. HbA1c
This test reflects the average glucose level in the three months 
prior to measurement. It is correlated with the risk of congenital 
malformations, not to any other adverse pregnancy outcomes. 
It is best used for pregnancy planning and prenatal follow-up in 
cases of diabetes in pregnancy. HbA1c does not replace the OGTT 
for the diagnosis of GDM. However, in women with GDM, HbA1c 
may be used to verify the reliability of their self-monitored 
glucose reports [11,12].
7.2.2. Self-monitoring of blood glucose
Self-monitoring of capillary glucose is achieved by multiple 
daily measurements of capillary blood glucose with a handheld 
glucometer. It only provides glucose values at the time of 
measurement and misses in between hyper/hypoglycemic 
events. Multiple studies have shown the utility of self-monitoring 
of blood glucose in achieving tight glycemic control to reduce 
pregnancy complications [13–16].
7.2.3. Continuous glucose monitoring
The device consists of a subcutaneous enzymatic sensor 
attached to a nonimplanted transmitter that sends readings 
to a receiver and provides numerous automated readings of 
interstitial tissue glucose, calibrated to reflect plasma glucose. 
The continuous measurement enables detection of virtually 
all glucose fluctuations and helps modify treatment [17–19]. 
Continuous glucose monitoring may help achieve a small HbA1c 
reduction in a nonpregnant population [20,21]. It can detect high 
postprandial blood glucose levels and nocturnal hypoglycemia 
[22,23]. However, no clear maternal or neonatal benefits have 
been reported during pregnancy in women with GDM [24,25].
7.2.4. Recommendations for glucose monitoring in women with GDM
The issue of the optimal daily frequency and timing in 
relationship to a meal for checking blood glucose in women 
with GDM remains unresolved. There is no “evidence” from 
a randomized controlled trial (RCT) to support any specific 
frequency. In the two RCTs for the management of GDM, the 
study by Landon et al. [26] stated that patients were instructed to 
test themselves fasting and 2 hours postprandial, without stating 
how often they should test throughout the day; the ACHOIS study 
[27] recommended that patients should monitor their home 
blood glucose levels initially four times a day and then used “daily 
Box 4
Recommendations for timing and mode of delivery in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
As per local protocol or as suggested in Figure 4 All 2|
38−39 weeks 
3800−4000 g or large 
for gestational age 











Continue to 40−41 
weeks
Induce labor Offer elective 
cesarean delivery
Figure 4 Timing of delivery in women with gestational diabetes mellitus and diabetes in pregnancy.
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monitoring at rotating times.” In an observational study, Langer 
et al. [28] requested patients to test themselves seven times a 
day (although they actually tested themselves at a mean of 4.2 
times a day). Guidelines are also equivocal. The National Institute 
for Health and Care Excellence (NICE) suggests that personnel 
should “advise women who need intensification of hypoglycemic 
therapy to increase the frequency of self-monitoring to include 
fasting and a mixture of pre- and post-prandial levels” [29]. 
ACOG states [1] “There is insufficient evidence concerning the 
optimal frequency of blood glucose testing of GDM. Based on 
the data available the general recommendation is four-times 
daily glucose monitoring performed at fasting and either at 
1-hour or 2-hour intervals after each meal. Once the patient’s 
glucose levels are well-controlled by her diet, the frequency of 
glucose monitoring can be modified.” In its 2015 clinical practice 
recommendations, the ADA encourages pre- and postprandial 
monitoring of blood glucose but does not recommend a specific 
frequency of testing [30].
The recommendations for glucose monitoring in women with 
GDM are shown in Box 5.
7.3. Targets of therapy
The main goal for treatment of GDM is to prevent adverse 
effects on the mother and fetus; the most important and proven 
factor to achieve this goal is reduction of glucose levels without 
undue hypoglycemia. This should be achieved throughout 
pregnancy and during labor and delivery. Attempts must be 
made to achieve glucose levels as close as possible to those seen 
in normal pregnancy.
7.3.1. Glucose control during pregnancy
Elevated glucose values, specifically postprandial glucose 
levels, are associated with adverse pregnancy outcomes in 
patients with hyperglycemia in pregnancy [31–33]. Data suggest 
that postprandial glucose levels are more closely associated with 
macrosomia than fasting glucose levels [34,35]. No controlled 
study has, as yet, established the optimal plasma glucose level(s) 
to prevent increased fetal risk.
7.3.2. Glucose control during labor and delivery
Neonatal hypoglycemia develops as a consequence of the 
heightened fetal insulin response to cope with transplacental 
transfer of high maternal glucose. After delivery, the sudden 
decrease in glucose supply to the newborn in the midst of high 
insulin levels of fetal origin results in hypoglycemia [35,36]. 
Several observational trials have studied the correlation between 
glucose levels during labor and neonatal outcomes [37–43]. 
There is general agreement that maternal hyperglycemia during 
labor and delivery is associated with neonatal hypoglycemia, 
in both GDM [37] and T2DM [38–41]. Other reports show that 
maternal hyperglycemia during labor is also associated with 
birth asphyxia and nonreassuring fetal heart rate tracings [42,43]. 
In women with type 1 diabetes (T1DM) it has been shown that 
targeting maternal glucose levels in the range of 4.0−7.0 mmol/L 
(72−126 mg/dL) during labor is associated with a lower risk of 
maternal hypoglycemia than lower target levels [44]. In addition, 
these levels during labor and delivery are helpful in reducing 
the incidence of neonatal hypoglycemia, birth asphyxia, and 
nonreassuring heart rate tracings. Glycemic targets for women 
with GDM are given in Box 6.
7.3.3. Weight gain
The epidemic of obesity adversely affects the health of 
an entire population, but has important consequences for 
pregnancy and postpartum outcomes [45]. Overweight and obese 
women before pregnancy are at an increased risk for pregnancy 
complications including diabetes, hypertensive complications, 
stillbirth, and increased risk for cesarean delivery. The Institute 
of Medicine (IOM) has published recommendations for weight 
gain during pregnancy, based on prepregnancy body mass index 
[46]. There is no evidence for recommendations for weight gain 
specific to pregnancies complicated by diabetes. According to 
IOM guidelines for weight-appropriate and underweight women, 
to ensure normal infant birth weight a recommended weight 
gain with no restriction in caloric intake is recommended. For 
overweight and obese women there is no consensus regarding 
caloric intake and weight gain during pregnancy. Some evidence 
suggests that weight reduction may be appropriate [47], whereas 
other studies indicate that in overweight and obese women, 
weight loss or gain of less than or equal to 5 kg during pregnancy 
is associated with an increased risk of SGA and decreased 
neonatal fat mass, lean mass, and head circumference [48]. 
Recommendations for weight gain during pregnancy and during 
pregnancy in women with GDM are given in Boxes 7 and 8.
7.4. Lifestyle modification
7.4.1. Nutritional therapy
Nutritional therapy includes an individualized food plan to 
optimize glycemic control. It should be based on personal and 
cultural eating habits, physical activity, blood glucose measure-
ments, and the expected physiological effects of pregnancy on the 
woman and her fetus. Medical nutritional therapy in pregnancy 
can be described as “a carbohydrate-controlled meal plan that 
promotes adequate nutrition with appropriate weight gain, 
Box 5
Recommendations for glucose monitoring in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Self-monitoring of blood glucose is recommended for all pregnant women with 
diabetes, 3−4 times a day:
• Fasting: once daily, following at least 8 hours of overnight fasting
• Postprandial: 2-3 times daily, 1 or 2 hours after the onset of meals, rotating 
meals on different days of the week
All 2|
Self-monitoring of blood glucose is recommended for all pregnant women with 
diabetes at least once daily, with documented relation to timing of meal
Low 2|
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normoglycemia, and the absence of ketosis” [49]. Nutritional 
intervention for diabetes, specifically pregnancy complicated 
with diabetes, is consistently considered a fundamental treat-
ment modality [50–53]. It is the first-line therapy in all women 
diagnosed with GDM [54–55]. However, there is paucity of data 
to provide evidence-based recommendations for most of the 
nutrition interventions. Studies that have examined the impact of 
nutritional practice guidelines demonstrate improved metabolic 
control for T1DM and T2DM [56,57], as well as a positive impact 
on the metabolic goals of GDM [58].
7.4.2. Calories
Restricting calories has been a strategy for controlling weight 
gain, glucose levels, and avoiding macrosomia in women with 
GDM and their babies. Successful pregnancy outcomes have 
been reported within a wide range of caloric intake ranging from 
1500−2800 calories per day [59–64]. However, most studies 
were small sized, uncontrolled, and relied on self-reported 
dietary intakes. Existing data suggest that severe caloric 
restriction (less than 1500 calories/day or 50% restriction) 
increases ketonemia. This is of particular significance in women 
with T1DM in pregnancy where high levels of third trimester 
ketone bodies may impair mental development of the offspring 
[60]. Modest caloric restriction (1600−1800 calories/day, 33% 
reduction) does not lead to ketosis [65,66]. Daily energy intake 
of approximately 2050 calories in all BMI categories in women 
with GDM was reported to reduce weight gain, maintain 
euglycemia, avoid ketonuria, and achieve average birth weights 
of 3542 g [67,68].
Box 6
Recommendations for glycemic targets for gestational diabetes mellitus.a
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Targets for glucose control during pregnancy:
• Fasting glucose <5.3 mmol/L (95 mg/dL)
• 1-hour postprandial <7.8 mmol/L (140 mg/dL)
• 2-hour postprandial <6.7 mmol/L (120 mg/dL) 
All 1|
Educate to recognize and treat signs of hypoglycemia:
• Ingest 15 g of simple carbohydrate (sugar, rapidly absorbed tablets, 
sweetened liquids)
All 1|
Teach family members how to use the glucometer All 2|
Target for glucose control during labor and delivery:
• 4–7 mmol/L (72−126 mg/dL)
All 1|
a Source: American Diabetes Association [30].
Box 8
Recommendations for weight gain during pregnancy with diabetes.a
Recommendations Resource setting Strength of recommendation 
and quality of evidence
Institute of Medicine revised guidelines for weight gain during pregnancy All 2|
Weight reduction for obese and overweight women prior to pregnancy All 1|
a Source: Institute of Medicine [46].
Box 7
Institute of Medicine recommendations for weight gain during pregnancy.a
Prepregnancy body mass indexb Total weight gain, Kg Mean (range) rates of weight gain at the 
second and third trimester, kg/weeks)
Underweight <18.5 12.5−18 0.51 (0.44−0.58)
Normal weight 18.5−24.9 11.5−16 0.42 (0.35−0.50)
Overweight 25.0−29.9 7−11.5 0.28 (0.23−0.33)
Obese ≥30.0 5−9 0.22 (0.17−0.27)
a Source: Institute of Medicine [46].
b BMI calculated as weight in kilograms divided by the height in meters squared.
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7.4.3. Carbohydrates
Focusing on total amount, quality, and distribution of 
carbohydrate intake helps achieve metabolic control in all 
patients with diabetes. The total amount of carbohydrates, 
distribution of carbohydrates in different meals and snacks, 
type of carbohydrates, and the glycemic index (GI) of foods can 
all be modified without affecting the total caloric intake [69]. 
Carbohydrates should be distributed throughout the day in three 
small- to moderate-sized meals and 2−4 snacks. An evening 
snack may be needed to prevent accelerated ketosis overnight. A 
minimum of 175 g carbohydrates/day should be provided, which 
is higher than the 130 g/day recommended for nonpregnant 
women [70].
7.4.4. Glycemic index
The glycemic index of a food is defined as the area under 
the two-hour blood glucose curve (AUC) following a 12-hour 
fast and ingestion of a food with a certain quantity of available 
carbohydrate (usually 50 g). The AUC of the test food is divided 
by the AUC of the standard (either glucose or white bread, giving 
two different definitions) and multiplied by 100. The average 
GI value is calculated from data collected in 10 human subjects. 
Both the standard and test food must contain an equal amount of 
available carbohydrate and usually ranges between 50 and 100. 
The GI of foods is also an important factor, as food with a low GI 
may reduce postmeal glycemic excursion and flatten the glucose 
curve. Foods with a high GI (>70) may show higher postprandial 
values, while low GI diets in nonpregnant patients with diabetes 
lead to an additional 0.4% reduction in hemoglobin A1c [71]. Low 
GI diet has been shown to reduce birth weight [72–74] and cause 
a two-fold increase in rates of underweight for gestational age 
babies in nondiabetic women [74]. By extrapolation, this may 
provide an advantage in reducing macrosomia in women with 
GDM and diabetes in pregnancy. Low GI diets are associated 
with less frequent insulin use and lower birth weight than 
in control diets, suggesting that it is the most appropriate 
dietary intervention to be prescribed to patients with GDM 
[75]. Pregnancy does not change the GI values of specific foods. 
However, due to the wide interindividual variability in the 
GI, each woman needs to determine which foods to avoid or 
consume in smaller portions at all meals or during specific times 
of the day, for the duration of her pregnancy [76].
7.4.5. Fiber
Fiber intake, particularly soluble fiber, is beneficial in 
lowering serum lipid levels and reducing glucose excursions. 
Low GI foods often have higher fiber content. While good quality 
studies are not available to determine the benefits of fiber-rich 
diets in pregnant women with diabetes, preference should be 
given to foods rich in fiber. Up to 28 g fiber intake per day is 
recommended for pregnant women [77]. Fiber also helps reduce 
constipation, which is a common problem in pregnancy.
7.4.6. Nutritional education
While providing individual diet counseling is the ideal 
option, it is most often not feasible because of lack of resources. 
Women with GDM and DIP must receive practical education 
that empowers them to choose the right quantity and quality 
of food. This can be achieved through teaching portion sizes or 
using the plate model and a culturally appropriate food pyramid 
or color coding of food. Nutritional education should emphasize 
healthier cooking methods and reduction or moderation in 
consumption of processed, high sugar, high fat, high salt, and 
low fiber foods. It is important to highlight that women with 
GDM be advised (repeatedly during pregnancy) to continue the 
same healthy eating habits even after delivery to reduce the risk 
of future T2DM and metabolic syndrome. Recommendations for 
nutrition therapy in women with GDM are given in Box 9.
7.4.7. Physical activity
Physical activity in nonpregnant patients with diabetes 
has been shown to improve metabolic control, reduce insulin 
resistance, reduce cardiovascular risk, and improve weight 
control and overall well-being [78]. Women with GDM may 
achieve reduced glucose levels (up to 1.3 mmol/L [23 mg/
dL]) with 30 minutes of physical activity [79]. A recent meta-
analysis suggested that physical activity in pregnancy provided 
a slight protective effect against the development of GDM. 
Studies evaluating type, timing, duration, and compliance 
with physical activity regimens are warranted to best inform 
obstetric guidelines [80]. Regular aerobic exercise with proper 
warm-up and cool-down has been shown to lower fasting and 
postprandial glucose concentrations in several small studies of 
previously sedentary women with GDM. Safety of prescribed 
exercises for glucose management has not been demonstrated; 
therefore, women should be advised to monitor fetal activity and 
blood glucose levels before and after exercise. Increased physical 
activity postpartum in women with history of GDM is associated 
with significantly lower risk of progression to T2DM [81,82]. 
Recommendations for physical activity in women with GDM are 
given in Box 10.
7.5. Medical therapy
7.5.1. Oral antidiabetic agents
Traditionally, when dietary therapy was insufficient to 
maintain normoglycemia in women with GDM, insulin was 
the only available medical therapy [83–85]. In the past, oral 
antidiabetic agents (OAD) were not recommended during 
pregnancy owing to the fear of potential adverse fetal effects 
including teratogenicity and neonatal hypoglycemia [86–90]. 
Earlier evidence in support of OAD was weak and principally 
based on case series involving the use of first-generation 
sulfonylureas [86–88,91–95]. Although neither glyburide nor 
metformin are approved for use in pregnancy, their use as 
an adjunct therapy in GDM has been considered by several 
organizations. For example, glyburide has been acknowledged 
in the Fifth International Workshop-Conference on Gestational 
Diabetes Mellitus [96] and both are considered in the NICE 
guidance [97] and ACOG practice bulletin [1]. Use of oral agents 
is increasing, and in some settings they are the first option when 
drug treatment is required for women with GDM. In a large 
nationwide retrospective cohort study in the USA, including 
10 778 women with drug-treated GDM, use of glyburide 
increased from 7.4% in 2000 to 64.5% in 2011, becoming the 
most common treatment since 2007 [98].
• FIGO recognizes that nutrition counseling and physical 
activity are the primary tools in the management of GDM.
• FIGO recommends that women with GDM receive practical 
nutrition education and counseling that empowers them 
to choose the right quantity and quality of food.
• Women with GDM must be repeatedly advised to continue 
the same healthy eating habits after delivery to reduce the 
risk of future T2DM.
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7.5.1.1. Glyburide
This is a second generation sulfonylurea. Its transfer across the 
placental barrier was first evalu ated in single-cotyledon placental 
models, wherein no significant transfer of glyburide was found, 
even when maternal glyburide concentrations were much higher 
than the therapeutic con cen trations [99,100]. Following these 
observations, Langer et al. [101] conducted an RCT to compare 
the efficacy and safety of glyburide (n=201) and insulin (n=203) 
in the management of women with GDM. This study found no 
differences in the rate of maternal and neonatal adverse outcomes 
between the glyburide and insulin treated groups, as well as 
no detection of glyburide in cord blood. Furthermore, glycemic 
control and pregnancy outcomes were comparable.
Other studies [102,103] suggested that glyburide may be 
actively transported from fetus to mother and that the fetus 
may be exposed to about 9%−70% of the maternal concentration. 
Subsequently, these observations were confirmed in a series of 
clinical studies evaluating the outcome of infants born to mothers 
receiving glyburide during the second and third trimesters for 
GDM [104–107] as well as for T2DM [108]. A recent systematic 
review and meta-analysis [109] shows that comparing glyburide 
treatment with insulin results in about 100 g higher birth weight, 
two-fold higher neonatal hypoglycemia, and more than two-fold 
higher macrosomia in the glyburide group. The magnitude of the 
difference in these outcomes is relevant for clinical practice.
In head-to-head comparison between metformin and gly-
buride, the former was associated with less maternal weight 
gain (pooled mean difference −2.06 kg [95% CI, −3.98 to −0.14]), 
lower birth weight (pooled mean difference −209 g [95% CI, −314 
to −104]), less macrosomia (pooled risk ratio 0.33 [95% CI, 0.13 to 
0.81]), and fewer LGA newborns (pooled risk ratio 0.44 [95% CI, 
0.21 to 0.92]). The average treatment failure was 26.8% (48/179) 
Box 9
Recommendations for nutrition therapy in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
We recommend that the following principles should be adhered for all pregnant 
women with diabetes:
• Design an appropriate diet with respect to prepregnancy BMI, desired body 
weight, physical activity, habits, and personal and cultural preferences.
• Provide routine follow-up and diet adjustments throughout pregnancy to 
achieve and maintain treatment goals.
• Offer training, education, support, and follow-up by a qualifi ed dietician 
experienced in care of women with diabetes. Issues for discussion 
include: weight control, food records, carbohydrate counting, prevention of 
hypoglycemia, healthy foods, and physical activity.
All 1|
We suggest that caloric intake be calculated based on prepregnancy BMI and 
desirable weight gain as follows:
• 35−40 kcal/kg desirable body weight for underweight women
• 30−35 kcal/kg desirable body weight for normal weight women
• 25−30 kcal/kg desirable body weight for overweight women
All 2|
We recommend limiting carbohydrate intake to 35%–45% of total calories, with 
a minimum of 175 g carbohydrate per day, distributed in three small-to-moderate 
sized meals and 2−4 snacks.
All 1|
For obese women, caloric intake may be reduced by 30%, but not below 
1600−1800 kcal/d
All 2|
For women with diabetic nephropathy, protein may be lowered to 0.6−0.8 g/kg 
ideal body weight 
All 2|
Box 10
Recommendations for physical activity in women with gestational diabetes mellitus.
Recommendations Resource setting Strength of recommendation 
and quality of evidence
We suggest that appropriate, personally adapted, physical activity be 
recommended for all women with diabetes:
• Planned physical activity of 30 min/day
• Brisk walking or arm exercises while seated in a chair for 10 min after each 
meal.
• Women physically active prior to pregnancy should be encouraged to 
continue their previous exercise routine.
All 2|
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in the metformin group versus 23.5% (40/170) in the glyburide 
group. Metformin was associated with higher fasting blood 
glucose during treatment (pooled mean difference 0.15 mmol/L 
(0.00 to 0.30).
7.5.1.2. Metformin
Metformin has been shown to freely cross the placental 
barrier [110], reaching concentrations in fetal circulation of 50% 
or more of those measured in maternal serum. The fetus can be 
exposed to concentrations as high as or even higher than those 
measured in maternal serum [111]. Several studies have reported 
outcomes in women, mainly women with PCOS exposed to 
metformin at the time of conception and during early pregnancy 
[112–114]. The rates of adverse outcomes, including congenital 
malformations and neonatal hypoglycemia, were similar to those 
reported in the general population [112].
In the Metformin in Gestational Diabetes (MiG) trial, the 
largest RCT comparing metformin with insulin, Rowan et al. [115] 
randomized 751 women with GDM at 20−33 weeks to treatment 
with either metformin or insulin. Metformin was associated 
with a significantly lower rate of neonatal hypoglycemia (3.3% 
vs 8.1%; P<0.008), but with a higher rate of preterm birth (12.1% 
vs 7.6%; P=0.04) than insulin. There were no differences between 
the groups with regard to the rate of congenital anomalies or 
other serious maternal and neonatal adverse events. In a two-
year follow-up of offspring from the MiG trial, offspring of 
mothers treated with metformin had more subcutaneous fat 
in the shoulder and upper arm regions compared with those 
where the initial medical treatment was insulin [116]. A one-year 
follow-up of women and offspring from an RCT of women with 
PCOS treated with or without metformin during pregnancy [117], 
found that although women in the metformin group gained 
less weight during pregnancy, they had a higher BMI one year 
postpartum and that the offspring in the metformin group were 
significantly heavier (0.5 kg) at 1 year of age. Another similar but 
smaller study from the same authors found significantly higher 
fasting glucose in 8-year-old offspring of women treated with 
metformin [118].
In a meta-analysis of 10 studies that assessed the effect 
of exposure to metformin, the rate of congenital anomalies 
and neonatal mortality was not increased [119]. A prospective 
study of 126 infants of mothers treated with metformin for 
PCOS during pregnancy reported no adverse effects on the 
infants’ weight, length, motor activity, or behavior at the age of 
18 months [120]. In the MiG trial [115], the rate of composite 
neonatal morbidity (neonatal hypoglycemia, respiratory distress, 
need for phototherapy, birth trauma, 5-minute Apgar score <7, or 
prematurity) was comparable in the metformin and the insulin 
groups. In addition, there were no differences in the degree of 
glycemic control and in umbilical cord insulin levels between the 
metformin and insulin groups. Metformin was associated with 
a lower weight gain during pregnancy (0.4 ± 2.9 vs 2 ± 3.3 kg; 
P<0.001). Furthermore, the majority of women in the metformin 
group stated that they would choose to receive their assigned 
treatment again (76.6% vs 27.2%; P<0.001). Nevertheless, 
metformin was associated with a failure rate of 46.3% (defined as 
a requirement for additional insulin).
In a smaller and more recent randomized study comparing 
metformin with glyburide, Moore et al. [121] assigned 149 women 
with GDM who had failed diet treatment to either met formin 
or glyburide. The failure rate in achieving adequate glycemic 
control in the metformin group was 34.7%, which was more than 
two-fold higher than in the glyburide group (16.2%; P=0.01). In 
another recent RCT [122], 72 women with GDM were randomized 
for treatment with metformin or glyburide; the failure rate of 
metformin and glyburide was 25% and 23.8%, respectively.
Recently, Dhulkotia et al. [123] conducted a systematic 
review and meta-analysis of RCTs comparing the effects of oral 
hypoglycemic agents (glyburide and metformin) with insulin 
in GDM patients. Six studies comprising 1388 subjects were 
included in the analysis. There were no significant differences 
between the OAD and insulin groups with regard to maternal 
fasting or postprandial glycemic control, rate of neonatal 
hypoglycemia, birth weight, or rate of LGA infants. The authors 
concluded that glycemic control and pregnancy outcomes were 
similar for oral hypoglycemic agents and insulin. Moreover, 
they suggested that glyburide and metformin should be used 
as the first-line agents in GDM management. Furthermore, as 
oral hypoglycemic agents are considerably more convenient and 
less expensive than insulin [124] and do not require intensive 
education regarding their use at the time of therapy initiation; 
they are clearly preferred by most patients [125,126] and thus 
enhance treatment adherence. These advantages are particularly 
beneficial in situations where insulin is not readily available or 
when patients refuse insulin therapy.
Additionally, metformin may also significantly reduce several 
adverse maternal and neonatal outcomes, including pregnancy 
induced hypertension, neonatal hypo glycemia, and the need 
for NICU admission [119]. Treatment of GDM with metformin, 
compared with insulin, is associated with signifi cantly lower 
weight gain, and lower incidence of pregnancy induced 
hypertension, but with a higher rate of preterm labor [127]. 
In the meta-analysis by Balsells et al. [109], metformin—when 
compared with insulin—was associated with less maternal weight 
gain (pooled mean difference −1.14 kg [95% CI, −2.22 to −0.06]), 
lower gestational age at delivery (pooled mean difference −0.16 
weeks [95% CI, −0.30 to −0.02]), and more preterm births (pooled 
risk ratio 1.50 [95% CI, 1.04 to 2.16]). A trend was observed 
toward a lower rate of any neonatal hypoglycemia (pooled risk 
ratio 0.78 [95% CI, 0.60 to 1.01]); the average treatment failure 
in the metformin group was 33.8% (229/678). For secondary 
outcomes, metformin was associated with lower postprandial 
blood glucose (pooled mean difference −0.14 mmol/L [95% CI, 
−0.22 to −0.05]), less maternal weight gain since study entry 
(pooled mean difference −1.23 kg [95% CI, −1.72 to −0.73]), less 
pregnancy induced hypertension (pooled risk ratio 0.53 [95% CI, 
0.31 to 0.90]), and less severe neonatal hypoglycemia (pooled 
risk ratio 0.62 [95% CI, 0.42 to 0.94]) [109].
7.5.1.3. Recommendations for pharmacological treatment
In the short term, in women with GDM requiring drug 
treatment, glyburide seems inferior to both insulin and metformin, 
while metformin (plus insulin when required) performs slightly 
better than insulin [109]. Recommendations for pharmacological 
treatment in women with GDM are given in Box 11.
It is important to note that there is no long-term evidence 
on the safety of OADs.
7.5.2. Insulin therapy
When blood glucose targets cannot be reached by diet and/
or OADs, insulin is required. There is no evidence supporting 
the advantages of any one type of insulin or regimen of insulin 
over another. Thus, insulin type and regimens should be 
individualized [128–131]. It is beneficial to pair rapid-acting 
with intermediate or long-acting insulin, in order to simulate 
the physiologic insulin secretion throughout the day. In 
women with diabetes, insulin requirements gradually increase 
throughout pregnancy: 0.7 units/kg/day in the first trimester; 
0.8 units/kg/day from week 18; 0.9 units/kg/day from week 
26; and 1.0 units/kg/day from week 36 until delivery. In some 
instances lower doses may suffice.
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Regular soluble human insulin and neutral protamine 
Hagedorn (NPH) human insulin are commonly used for treating 
diabetes during pregnancy. However, the action of regular human 
insulin is too slow to control peak postprandial blood glucose. 
However, lower postprandial maternal glucose concentrations 
with rapid-acting insulin analogs have not been associated with 
a diminution in adverse maternal, fetal, or perinatal outcomes. 
Although NPH is considered as intermediate acting insulin 
[132], its basal insulin action in pregnant women may require 
2−3 daily injections. Consequently, the risk of hypoglycemia is 
increased, particularly at night. These disadvantages in human 
insulin can be overcome by the use of short-acting (lispro and 
aspart) and long-acting (detemir and glargine) insulin analogues, 
or continuous insulin infusion in a pump.
7.5.2.1. Insulin lispro
Transplacental transport of lispro appears to be minimal 
[133–135], and without documented teratogenic effects [136] 
or adverse maternal outcome [137,138]. Women receiving lispro 
were reported to have a significantly lower area under the curve 
for glucose, insulin, and C-peptide compared with women 
treated with regular human insulin [139–142] and similar 
pregnancy outcomes [143,144].
7.5.2.2. Insulin aspart
Pettitt et al. [145] were the first to compare the efficacy of 
insulin aspart with that of regular human insulin in 15 women 
with GDM, demonstrating improved glycemic control with 
insulin aspart. The Insulin Aspart Pregnancy Study Group 
conducted the largest evaluation to date of insulin aspart use in 
pregnancy. A total of 322 women with T1DM were randomized 
to receive either insulin aspart or regular insulin. The rates of 
major congenital malformations [146], maternal and cord blood 
levels of insulin antibodies [147], hypoglycemic events, and 
pregnancy outcomes were comparable, while glycemic control 
was improved in the group receiving insulin aspart [148]. Based 
on the results of this study, the FDA changed the pregnancy use 
warning from category C to category B.
7.5.2.3. Insulin detemir
Insulin detemir is a long-acting insulin analogue that was 
first evaluated in pregnancy involving 10 women with T1DM 
treated throughout pregnancy [149]. No adverse maternal or 
neonatal effects were documented. Several RCTs in nonpregnant 
women have shown that, compared with NPH insulin, detemir 
is associated with a lower rate of hypoglycemia and less weight 
gain [150–152]. In 2014, a large RCT compared insulin detemir 
with human NPH insulin, and demonstrated its efficacy and safety 
during pregnancy in women with T1DM [153]. No specific safety 
issues were identified [154]. Use in GDM has not been specifically 
investigated but is expected to have the same efficacy and safety 
as demonstrated in pregnant women with T1DM [155].
7.5.2.4. Insulin glargine
There is paucity of data on the use of insulin glargine during 
pregnancy. From the limited studies, however, it appears to be 
safe and well tolerated [156,157].
7.5.2.5. Recommendations for insulin treatment
Recommendations for insulin treatment in women with GDM 
are given in Box 12.
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The postpartum period is crucial, not only in terms of 
addressing the immediate perinatal problems, but also in the 
long term for establishing the basis for early preventive health 
for both mother and child, who are at a heightened risk for 
future obesity, metabolic syndrome, diabetes, hypertension, and 
cardiovascular disorders.
8.1. Immediate postpartum period
8.1.1. Infections
Mothers with diabetes have an increased risk of infection 
and thus require extra attention in order to detect early signs 
of genitourinary, uterine, and surgical site infections (episiotomy 
and cesarean delivery), particularly if the delivery has been 
prolonged or required operative intervention. Women with 
diabetes in pregnancy are at a higher risk compared with women 
with GDM. The large-sized offspring of diabetic mothers do not 
suckle well; this may lead to milk retention and higher risk of 
breast abscess. Apart from neonates with infant respiratory 
distress syndrome or those with aspiration during birth, the risk 
of infection in the offspring of diabetic mothers is no higher than 
in the offspring of nondiabetic women [1].
8.1.2. Breastfeeding
Mothers with GDM and diabetes in pregnancy should 
be encouraged and supported in initiating and maintaining 
breastfeeding. Breastfeeding has been shown to be protective 
against the occurrence of infant and maternal complications 
[2], including reduction in childhood obesity, T2DM, and 
even T1DM [3–6]. Moreover, breastfeeding helps postpartum 
weight loss. Treatment with insulin or commonly used OADs, 
such as glyburide and metformin, is not a contraindication to 
breastfeeding as levels of OAD medications in breast milk are 
negligible and do not cause hypoglycemia in the baby.
8.1.3. Contraception
Women with GDM and diabetes should be encouraged to 
space their pregnancies in order to maintain and achieve optimal 
health between pregnancies. This also helps reduce the risk of 
GDM or diabetes in a subsequent pregnancy. In women with 
diabetes, pregnancy planning helps ensure that conception can 
occur when the mother’s metabolic health is optimal to reduce 
risks of spontaneous abortions or congenital malformations. 
These women must have access to and should receive advice 
about safe and effective methods of contraception [7,8]. With 
advances in contraceptive technology, clinicians can now offer 
their patients a relatively large range of options ensuring efficacy, 
efficiency, and satisfaction with regard to individual preferences.
8.1.4. Postpartum glucose testing
For all women diagnosed with hyperglycemia for the first 
time during pregnancy (GDM and diabetes in pregnancy), the 
glycemic status should be re-evaluated with a 75-g oral OGTT 
at 6−12 weeks after delivery [9,10]. Diagnosis at that time 
should be based on the currently recommended WHO criteria 
for diabetes [11], impaired fasting glucose (IFG), and impaired 
glucose tolerance (IGT) in the nonpregnant state. Women 
who do not have diabetes or pre-diabetes, according to these 
definitions, are still at risk of progression to diabetes and other 
cardiovascular problems and require ongoing surveillance [10] 
according to local protocol. There is no clear guidance about the 
type of tests (should these women undergo annual OGTTs, or can 
fasting plasma glucose or HbA1c measurement suffice?) or the 
frequency and duration for ongoing surveillance. When guidance 
exists it is often glucose centric, missing out other important 
parameters but most importantly it is poorly implemented.
8.1.5. Reducing long-term risk of T2DM and cardiovascular disease
Irrespective of the glycemic status on early postpartum 
testing, it should be assumed that women with GDM have the 
same or a higher level of future risk of diabetes and cardiovascular 
disease as people with pre-diabetes and they should be advised 
to maintain a healthy lifestyle with an appropriate diet, regular 
exercise, and normal body weight. Furthermore, to ensure optimal 
health before attempting their next pregnancy they should seek 
consultation with healthcare providers knowledgeable about 
diabetes prevention prior to discontinuation of contraception.
Progression to diabetes is more common in women with a 
history of GDM compared with those without a GDM history. 
Both “intensive lifestyle” and metformin have been shown 
to be highly effective in delaying or preventing diabetes in 
women with IGT and a history of GDM [12]. Data from the 
Diabetes Prevention Program Outcomes Study (DPPOS) have 
been published [13] and show that the benefits of lifestyle 
intervention and metformin seen in the DPP study continue 
over a longer period. DPPOS is a long-term follow-up of the DPP 
participants to investigate whether the delay in the development 
of diabetes observed during DPP is sustained and to assess the 
long-term effects of the interventions on health. DPPOS followed 
participants from the DPP study for an additional 7 years, during 
which time the lifestyle and metformin groups were encouraged 
to continue those interventions, and all participants were offered 
group lifestyle classes. Over 10 years, women with history of 
GDM assigned to placebo had a 48% higher risk of developing 
overt diabetes compared with women without a history of 
GDM. In women with a history of GDM, “intensive lifestyle” 
and metformin reduced progression to diabetes compared with 
placebo by 35% and 40%, respectively. Among women without a 
history of GDM, “intensive lifestyle” reduced the progression to 
diabetes by 30%, while metformin did not reduce the progression 
to diabetes [13].
As part of the ongoing Diabetes and Women’s Health Study, a 
cohort of 4554 women from the Nurses’ Health Study II who had 
a history of GDM were followed up from 1991 to 2007. Compared 
with women who maintained their total physical activity levels, 
women who increased their total physical activity levels by 
7.5 MET-h/wk or more (equivalent to 150 minutes per week of 
moderate intensity physical activity) had a 47% lower risk of 
T2DM (RR 0.53; 95% CI, 0.38−0.75); the association remained 
significant after additional adjustment for BMI [14]. Increasing 
physical activity might have lowered the risk of progression from 
GDM to T2DM.
Postpartum care is a critical area that should not be 
overlooked because of the long-term and intergenerational 
consequences. However, there are many barriers to achieving 
• FIGO supports the concept that the postpartum period 
in women with GDM provides an important platform to 
initiate early preventive health for both the mother and 
the child who are both at a heightened risk for future 
obesity, metabolic syndrome, diabetes, hypertension, and 
cardiovascular disorders.
8. Postpartum management
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this objective [15]. Following delivery, women with GDM seldom 
present with diabetes; and they are no longer pregnant therefore 
unlikely to visit physicians or obstetricians for check-ups. They 
are thus likely to be considered lost to follow-up. However, these 
women do visit health services focused on the well-being of 
their babies (for instance for the child’s vaccination program and 
to monitor the child’s growth and development) and are likely to 
do so at regular intervals for at least 5 years [16]. Obstetricians, 
family physicians, internists, pediatricians, and other healthcare 
providers must link postpartum follow-up of a GDM mother 
with the child’s vaccination and routine pediatric care program, 
to ensure continued follow-up and engagement of the high-risk 
mother−child pair.
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• FIGO encourages obstetricians to establish connections 
with family physicians, internists, pediatricians, and 
other healthcare providers to support postpartum follow-
up of GDM mothers linked to the regular check-up and 
vaccination program of the child to ensure continued 
engagement of the high-risk mother−child pair.
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Preconception care is a set of assessment measures and 
interventions undertaken prior to conception. These are aimed 
at identifying and modifying medical, behavioral, and social 
risks to women’s health during pregnancy, which may prevent 
or mitigate adverse pregnancy outcomes [1].
Pregnancies should be planned and maternal assessment 
with possible interventions should occur prior to conception to 
improve pregnancy outcome and maternal health [2]. This may 
not only improve immediate maternal, perinatal, and neonatal 
outcomes, but possibly may have long-term beneficial effects 
on both the mother and her baby, lasting well into adulthood 
and impacting next generation offspring, through epigenetic 
changes and intrauterine fetal programming. Key organizations 
have published extensive guidelines and recommendations 
for preconception care, including the American Academy of 
Pediatrics, ACOG, and the Centers for Disease Control and 
Prevention [3–5]. It is estimated that 30%−90% of women have 
at least one condition or risk factor, such as anemia, under 
nutrition, obesity, diabetes, hypertension, and thyroid disorders, 
etc. that may benefit from an appropriate preconception 
intervention [6,7]. However, only 30%−50% of pregnancies are 
planned and receive proper preconception care [7–14]. The key 
challenge is increasing awareness and acceptance of the concept 
of preconception counseling and to increase affordability and 
access to preconception services to women of reproductive age.
Universal preconception care, as a concept, is still a challenge 
in most parts of the world, where a significant proportion of 
women do not have access to prenatal care or receive only one 
or two prenatal visits, the concept of preconception care is a far-
off goal but envisaged as an intervention that could dramatically 
change maternal and neonatal health and outcomes. Screening 
for conditions such as malnutrition, anemia, overweight and 
obesity, hypertension, diabetes, and thyroid dysfunction etc. 
may have a significant impact. For women with diabetes, 
preconception care is also cost-saving [15] and yet only half of 
the women with diabetes undergo appropriate preconception 
glycemic control [16].
Discussion on preconception care in the context of GDM not 
only has relevance in terms of ruling out pre-existing diabetes, 
but also in terms of identifying women who are at risk of GDM 
(as described earlier) and initiating treatment and preventive 
care. Only normalizing blood glucose levels in the preconception 
period and in early pregnancy will reduce the rate of congenital 
malformations seen with marked maternal hyperglycemia. In 
this context, postpartum care of GDM women is preconception 
care for a subsequent pregnancy. Preconception care as an 
opportunity for predicting and preventing noncommunicable 
diseases has been described in a review by Hader et al. [16]
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9. Preconception care
• FIGO calls for public health measures to increase 
awareness and acceptance of preconception counseling 
and to increase affordability and access to preconception 
services to women of reproductive age, as this is likely to 
have both immediate and lasting benefits for maternal and 
child health.
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Pregnancy offers a window of opportunity to provide maternal 
care services in order to reduce traditional maternal and 
perinatal morbidity and mortality indicators and also to address 
intergenerational prevention of noncommunicable diseases, such 
as diabetes, hypertension, cardiovascular disease, and stroke. The 
relevance of GDM as a priority for maternal health and its impact 
on the future burden of noncommunicable diseases is no longer 
in doubt; but how best to deal with the issue remains relatively 
unclear as there are many unanswered questions. The available 
evidence is often not definitive, thorough, or based on optimum 
quality data. There are many gaps in this realm of knowledge. 
However, this should not be an excuse for inaction.
The FIGO Initiative on GDM is based on current available 
evidence and best practice, expert opinion, and consensus. FIGO 
acknowledges that there are major gaps in knowledge on how 
best to prevent, diagnose, and manage GDM to optimize care and 
outcomes, before, during, and after pregnancy for the immediate 
and long-term health of both a mother and her offspring. These 
questions can best be answered only through further research in 
pregnancy to ensure that the window of opportunity mentioned 
above is fully realized. FIGO encourages all relevant stakeholders 
to advocate, promote, support, carry out, and fund research 
to address the many knowledge gaps and research priorities 
identified and described in Appendix 3.
10. Research priorities
• FIGO encourages all relevant stakeholders to advocate, 
promote, support, carry out, and fund research to address 
the many knowledge gaps and research priorities in GDM.
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Appendix 1a
Experience from India: The Diabetes in Pregnancy Study Group in 
India (DIPSI) test
Asian Indians are considered to be at the highest risk of 
gestational diabetes. Based on studies from India and keeping in 
mind the already high burden and rising prevalence of diabetes 
and the realities of resource constraints within the health system 
in India, as well as the high rate of deliveries (27 million each 
year), the Diabetes in Pregnancy Study Group in India (DIPSI) 
developed the following guideline for diagnosis of GDM in the 
community [1]. This guideline has been endorsed by the Ministry 
of Health, Government of India, the Federation of Obstetrics and 
Gynecological Societies of India (FOGSI), and the Association of 
Physicians of India (API).
Who to test? The target population
All pregnant women in the community should be tested for 
hyperglycemia during pregnancy, i.e. there should be universal 
testing.
When to test?
Testing for GDM is recommended twice during prenatal care. 
The first testing should be done during first prenatal contact 
as early as possible in pregnancy. The second testing should be 
done ideally during 24−28 weeks of pregnancy if the first test is 
negative. If women present beyond 28 weeks of pregnancy, only 
one test is to be done at the first point of contact.
How to test?
Test for diagnosis should be simple, economical, and feasible 
both within the resource challenged public health system as well 
as the equally overburdened and busy private practice.
The Single Step Test measures plasma glucose 2 hours after 
ingestion of 75 g glucose dissolved in approximately 300 mL 
water irrespective of the last meal (fasting or nonfasting). In the 
absence of available laboratory facilities a plasma standardized 
glucometer may be used to evaluate blood glucose. A glucose 
level of ≤7.8 mmol/L or ≤140 mg/dL is taken as the cut-off for 
diagnosis of GDM.
Advantages of the DIPSI test
• Single test: Serves as both screening and diagnostic 
procedure (universal testing is possible). Fasting values 
alone fail to detect many women with GDM particularly in 
the Asian setting.
• Convenient and feasible: Most women do not come fasting 
for the prenatal visit [2]. When asked to come back again 
in the fasting state for the test, the dropout rate is high 
[3,4] owing to travel time and cost; even if women do come 
fasting, their fasting gets unduly prolonged because of clinic 
schedules and high patient volume, causing discomfort and 
inconvenience. The nonfasting test increases convenience 
as well as implementation feasibility. Using the glucometer 
provides an opportunity to communicate results instantly 
and initiate counseling right away, avoiding the need for the 
patient to return for test result.
Why the diagnostic cut-off point of 2 hour 75 g ≥7.8 mmol/L 
(140 mg/dL)?
• DIPSI guidelines were initiated before the WHO accepted 
and endorsed the IADPSG guideline and have now been 
ratified by the Ministry of Health and other professional 
bodies. The DIPSI guideline follows the old WHO 2 hour cut-
off value.
• A study to support the single nonfasting 2-hour 75-g 
test with a standard fasting 75-g OGTT was done using 
the ≥7.8 mmol/L (140 mg/dL) diagnostic cut-off, and 
demonstrated no statistically significant difference in the 
glycemic profile at 2 hours between the nonfasting and 
standard OGTT in the diagnosis of GDM [5,6].
• Given the positive relationship of poor pregnancy outcomes 
with increasing maternal plasma glucose values in short 
Asian Indian women with a relatively small pelvis, a cut-off 
value based on a lower odds ratio (1.5 of HAPO data) for 
macrosomia corresponding to a 2-hour value of 7.8 mmol/L 
or 140 mg/dL of the earlier WHO criteria is considered more 
appropriate to identify those at risk for macrosomia-related 
birth complications.
• Treatment of women with GDM identified with 2-hour 
post-75 g glucose cut-off values ≥7.8 mmol/L (140 mg/dL) is 
associated with reduced adverse pregnancy outcomes [7].
Appendix 1b
Experience from China: Using fasting plasma glucose values to 
reduce the number of OGTTs
China is facing a huge burden of diabetes. The overall 
prevalence of diabetes in the Chinese adult population is 
estimated to be 11.6%: 12.1% among men and 11.0% among women. 
The prevalence of pre-diabetes is 50.1% in Chinese adults: 52.1% 
in men and 48.1% in women. In approximately two-thirds of the 
cases, the condition had not previously been diagnosed [8]. Of 
the participants with undiagnosed diabetes (44.1% of men and 
50.2% of women), 46.6% have isolated increased 2-hour plasma 
glucose levels after an OGTT and a fasting glucose level alone 
would have failed to identify these cases [9]. As age of onset 
of diabetes is decreasing, the risk that young women may have 
undiagnosed T2DM when they become pregnant is quite real as 
is the risk of GDM. GDM prevalence in China has been reported 
to be as high as 17.5% [10].
The Ministry of Health in China published its recommendations 
for testing and diagnosis of GDM in 2011 [11]. According to this, 
fasting plasma glucose measurement or 75-g 2-hour OGTT 
should be taken at first prenatal visit to rule out pre-existing 
diabetes. Fasting plasma glucose ≥7.0 mmol/L or ≥126 mg/dL, 
or 75-g 2-hour OGTT ≥11.1 mmol/L or ≥200 mg/dL, or random 
plasma glucose ≥11.1 mmol/L or ≥200 mg/dL are considered 
diagnostic of pre-existing diabetes.
The diagnosis of GDM is based on a single-step 75-g 2-hour 
OGTT done between 24 and 28 weeks of pregnancy. The cut-off 
points for diagnosis of GDM are 0 hour: 5.1 mmol/L or 92 mg/
dL; 1 hour: 10 mmol/L or 180 mg/dL; and 2 hour: 8.5 mmol/L or 
153 mg/dL.
To reduce the number of OGTTs to be done among all pregnant 
women at 24 and 28 weeks of pregnancy it has been suggested 
that the fasting plasma glucose test may be done first using a 
rule in/rule out approach. If the fasting plasma glucose value is 
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less than 4.4 mmol/L or 80 mg/dL, no further testing is needed 
[12]. For values above 5.1 mmol/L or 92 mg/dL no further testing 
is needed and GDM can be diagnosed without an OGTT. Pregnant 
women with fasting glucose values between 4.4 and 5.1 mmol/L 
must undergo a 75-g 2-hour OGTT to further confirm or rule out 
GDM. Using this strategy, only half of pregnant women would 
require a formal OGTT [12]. If plasma-standardized glucometers 
are used, women requiring an OGTT based on the results of the 
fasting value may be administered the 75-g glucose load and 
further testing can be continued in the same sitting.
A comprehensive study from China [10] also showed that in 
Chinese women, a fasting plasma glucose value ≥5.1 mmol/L 
or ≥92 mg/dL at first prenatal visit cannot be used to diagnose 
GDM. The study shows that less than one-third of women with 
a fasting plasma glucose value >5.1 mmol/L or ≥92 mg/dL at 
the first prenatal visit showed a fasting plasma glucose value 
>5.1 mmol/L or ≥92 mg/dL at 24–28 weeks of pregnancy. Only 
38.9% of women with fasting plasma glucose between 5.1 and 
6.09 mmol/L (92−109 mg/dL) at first prenatal visit went on 
to develop GDM at 24 to 28 weeks; whereas about two-thirds 
(66.2%) of pregnant women with fasting plasma glucose values 
between 6.1 and 7.0 mmol/L (110−125 mg/dL) at first prenatal visit 
develop GDM at 24 to 28 weeks. The study proposes that women 
with fasting plasma glucose values ≥6.1 mmol/L and <7.0 mmol/L 
(110−125 mg/dL) at first prenatal visit may be considered to have 
GDM and be treated with diet and exercise. They must undergo 
a 75-g OGTT between 24 and 28 weeks of pregnancy to confirm 
the diagnosis of GDM. Half of the women with fasting plasma 
glucose between 5.6 and 6.09 mmol/L (92−109 mg/dL) developed 
GDM and should therefore be considered as a high-risk group 
for GDM. Proper attention must be paid to their nutrition and 
exercise and they must undergo a formal 75-g 2-hour OGTT 
between 24 and 28 weeks of pregnancy.
Appendix 1c
Latin American practice
At the time of booking/first trimester, a fasting plasma 
glucose test is done to rule out overt diabetes (≥7 mmol/L or 
>126 mg/dL).
• Values under 5.6 mmol/L or 100 mg/dL are considered 
normal and a 75-g 2-hour OGTT is done between 24 and 
28 weeks of pregnancy.
• Values between 5.6 and 6.9 mmol/L or 100 and 125 mg/dL 
are considered diagnostic for GDM.
Cut-off value for a 75-g 2-hour OGTT at 24 to 28 weeks:
• ≥7.8 mmol/L or ≥140 mg/dL is considered GDM.
• <140 mg/dL is normal. However, if the patient has risk 
factors, the test is repeated between 31 and 33 weeks.
The cut-off point 7.8 mmol/L or >140 mg/dL is supported 
by the ACHOIS trial [13] and the Brazilian Gestational Diabetes 
Study Group data [14] and other studies [15,16].
Preliminary data analysis from an ongoing multicenter study 
comparing maternal and neonatal outcomes in 4000 pregnant 
women in Latin America shows that the incidence of macrosomia 
among the offspring of mothers with fasting plasma glucose 
between 92 and 99 mg/dL and not receiving any treatment is 
similar to that of the whole population.
Appendix 1d
ADIPS consensus guidelines for the testing and diagnosis of 
hyperglycemia in pregnancy in Australia and New Zealand
The ADIPS consensus guidelines [17] recommend:
• Universal single-step testing with 75-g OGTT at 
24–28 weeks of pregnancy for all pregnant women not 
previously known to have prepregnancy diabetes or 
hyperglycemia in pregnancy.
• Women with risk factors for hyperglycemia in pregnancy 
should be tested early in pregnancy. Some of these 
risk factors include: prepregnancy BMI >30; previous 
macrosomia (baby with birth weight >4500 g or >90th 
centile); previous hyperglycemia in pregnancy; age 
≥40 years; Asian, Indian subcontinent, Aboriginal, Torres 
Strait Islander, Pacific Islander, Maori, Middle Eastern, 
non-white African ethnic background; family history of first 
degree relative with diabetes or a sister with hyperglycemia 
in pregnancy; PCOS etc. The method of testing must be 
based on clinical judgment, local healthcare policy, and 
possible risk stratification.
• The use of WHO 2013 recommendations for the 
classification and diagnosis of hyperglycemia first detected 
at any time during pregnancy.
Appendix 1e
National Institute for Health and Care Excellence (NICE) Guideline 3 
(UK)
NICE published an update to its 2008 guidance on Diabetes in 
Pregnancy on February 25, 2015 [18]. By the time this document 
became available publically the FIGO GDM Initiative writing 
group had finalized its document and recommendations, and did 
not have time to fully review this document.
The key features of the NICE Recommendations are the 
following:
• NICE guidance does not recommend universal testing for 
GDM.
• NICE guidance recommends early testing (as soon as 
possible after booking, whether in the first or second 
trimester) with a 75-g 2-hour OGTT only for women with 
history of GDM in a previous pregnancy and for women 
with glycosuria of 2+ or above on 1 occasion or of 1+ or 
above on 2 or more occasions detected by reagent strip 
during routine prenatal care in current pregnancy.
• NICE guidance recommends testing for GDM with a 75-g 
2-hour OGTT between 24 and 28 weeks of pregnancy only 
for women with the following risk factors:
– BMI >30
– Previous macrosomic baby weighing 4.5 kg or above
– Previous GDM
– Family history of diabetes (first-degree relative with 
diabetes)
– Minority ethnic family origin with a high prevalence of 
diabetes
• Cut-off values for diagnosing GDM are:
– Fasting plasma glucose ≥5.6 mmol/L or ≥100 mg/d
– 2-hour plasma glucose ≥7.8 mmol/L or ≥140 mg/dL
• In deciding on the recommendation for risk factor based 
testing versus universal testing and the cut-off values, the 
NICE guidance, apart from other available evidence, also 
relied on the cost-effectiveness of different testing options 
(universal versus risk factor based) and cut-off values 
primarily using data from the Hyperglycemia and Adverse 
Pregnancy Outcomes (HAPO) study centers in the UK and 
Australia—representing the population of the UK.
• NICE guidance does not distinguish between diabetes 
first diagnosed during pregnancy and GDM. Any level of 
glycemia above the cut-off levels diagnosed for the first 
time during the index pregnancy is considered GDM.
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Appendix 1f
Gestational diabetes: Situation in middle-eastern countries
The regional office of the WHO in Cairo lists 21 countries in 
the Eastern Mediterranean Region. They include countries that: 
(1) are affluent (e.g. Saudi Arabia, Qatar, UAE, Saudi Arabia, 
Oman, Kuwait); (2) have average income (Tunisia, Egypt, Syria, 
Lebanon, Morocco); and (3) have low income (Sudan, Somalia).
The prevalence of diabetes (and gestational diabetes) in the 
six richest countries in the Eastern Mediterranean Region is 
among the highest in the world, at approximately 20% [19]. The 
overall prevalence of GDM in all Eastern Mediterranean countries 
is 14.5% (3.5%−26.2%) using the WHO 1999 criteria. The follow-
up after delivery that could potentially reduce the epidemic of 
diabetes mellitus in these high-risk populations is poor.
In general, information about GDM guidelines and criteria 
for diagnosis are sketchy and, when present, outdated. Among 
the websites of the countries examined, none—including the 
WHO regional office in Cairo [20]—mentioned the International 
Association of Diabetes in Pregnancy Study Groups (IADPSG)/
WHO 2013 criteria.
A 2012 physician survey [21] assessed the current regional 
practices of screening, diagnosis, and follow-up of GDM and 
knowledge of HAPO and IADPSG within seven hospitals in UAE 
and one in Oman. Physicians used a multitude of criteria for GDM: 
National Diabetes Data Group (NDDG 1979), American Diabetes 
Association (ADA 2010), WHO 1999, Australasian Diabetes in 
Pregnancy Society (ADIPS 1998), and the New Zealand Society 
for Study of Diabetes (NZSSD 2011). There was no consistency 
within and between hospitals. Approximately 60% physicians 
were aware of HAPO or IADPSG. More awareness and education 
of caregivers would make the discordant approach to GDM 
(within and between hospitals) more harmonious.
Appendix 1g
The European Board and College of Obstetrics and Gynaecology 
(EBCOG) proposal on screening for gestational diabetes and on the 
management for obesity
Developing a consensus on screening for GDM in Europe 
is challenging owing to diversity of ethnic populations and 
healthcare delivery systems across Europe. After the WHO 
2013 recommendations were released, many national societies 
within Europe have either revised or are considering revising 
their guidelines. However, most national societies in Europe do 
not recommend a universal one-step screening strategy with an 
OGTT, in part because of the associated workload and costs.
A steering committee, appointed by EBCOG, has developed a 
proposal for the use of uniform diagnostic criteria for GDM in 
Europe [22].
Screening for overt diabetes in early pregnancy
Since the frequency of obesity and T2DM in young adults is 
increasing in Europe and as the use of a simple screening test will 
lead to more women being timely diagnosed with overt diabetes, 
the steering group recommends screening for overt diabetes at 
preconception or at first prenatal contact, especially in high-risk 
groups using the cut-off values for diabetes outside pregnancy.
Due to the lack of clear evidence on which women would 
benefit most from screening and treatment of GDM in early 
pregnancy and which screening strategy for GDM should be used, 
the steering group has not made any recommendations on which 
diagnostic criteria for GDM should be used in early pregnancy.
Criteria for gestational diabetes in Europe at 24-28 weeks of 
pregnancy
In the belief that use of a uniform 2-hour 75-g OGTT in 
pregnancy with the same diagnostic criteria across Europe will 
lead to simplification and facilitate research on GDM within 
Europe, EBCOG has proposed the use of the 75-g OGTT and WHO 
2013 diagnostic criteria for GDM at 24−28 weeks of pregnancy. 
However, owing to lack of consensus, no clear recommendation 
has been made on whether universal one-step, two-step, or a 
selective risk factor-based screening approach should be used.
Postpartum screening strategy for glucose intolerance in women 
with a history of GDM
The current EBCOG proposal is to screen women with a history 
of GDM at 6−12 weeks postpartum using the 2-hour 75-g OGTT 
with nonpregnancy diagnostic criteria. Women with a history 
of GDM should have lifelong screening for the development of 
diabetes or prediabetes, at least every 3 years. As currently there 
is insufficient evidence to recommend one test over the other; 
HbA1C, FPG, or 75-g 2-hour OGTT are all considered appropriate 
to test for diabetes and prediabetes in the postpartum period. 
Women with a history of GDM found to have prediabetes should 
receive specific lifestyle interventions with or without metformin 
to prevent diabetes. EBCOG has also developed standards of care 
for obese women [23] and recommends these be taken into 
account when providing postpartum care.
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The GeDiForCE (Novo Nordisk, Denmark) model is an 
Excel-based (Microsoft, Redmond, USA) mathematical model 
developed to estimate the cost and health impact of various 
GDM screening and management choices [1]. The model aims 
to inform policy makers regarding GDM screening strategies 
and guidelines. GeDiForCE can compare alternative screening 
algorithms, prenatal interventions, and postpartum preventive 
lifestyle interventions. It estimates the cost per year of screening 
and interventions, perinatal complications, and cases of T2DM. 
It also calculates averted disability-adjusted life-years (DALYs).
The model is structured using a decision tree flowing from 
testing, to prenatal interventions and perinatal outcomes, to 
postpartum interventions and long-term T2DM outcomes. Key 
inputs include test sensitivity and specificity, health outcome 
risks, and intervention efficacy in reducing those risks—all 
derived from literature. A previously developed diabetes model, 
the CORE model [2], is used to assess the costs and health effects 
related to T2DM that occur after pregnancy in the mother and 
her offspring.
For every use, the GeDiForCE model will be populated with 
setting-specific data on GDM prevalence and cost of GDM 
screening and management. The model has been piloted in five 
different healthcare facilities in India and Israel. An analysis 
of the cost-effectiveness of GDM screening in urban China 
was presented at the Diabetes in Pregnancy (DIP) Symposium 
in Berlin, April 2015, concluding that GDM screening and 
interventions are cost-saving in an urban Chinese setting by 
IADPSG standards [3].
Development of GeDiForCE
The model was developed by health economic experts 
and the overall design of the model was reviewed by a group 
of international experts in mathematical modelling, health 
economics, gestational diabetes risk and management, and 
public health, in Stockholm, September 2010, and at workshops 
held at the Diabetes in Pregnancy (DIP) symposia in 2011 and 
2013. The model was subsequently modified according to the 
inputs received.
The development of the GeDiForCE model was funded by Novo 
Nordisk A/S. The model is made available for use free of charge 
and can be downloaded at: www.changingdiabetesaccess.com
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Needs, capacity, and resource assessment
It is acknowledged that the increased prevalence of 
hyperglycemia in pregnancy, even with potential revised models 
of care, will have resource implications. FIGO calls for action by 
national associations in collaboration with other stakeholders 
to support and undertake comprehensive national review of 
capacity, training needs, and obstetric and neonatal resource 
allocations relating to hyperglycemia in pregnancy.
Options for risk stratification
Not all cited risk factors for hyperglycemia in pregnancy are 
likely to be of equivalent predictive value and further research 
is required to determine whether some risk factors could be 
designated “high.” The ability and accuracy of obstetric care 
providers to conduct early pregnancy testing for hyperglycemia 
in pregnancy based on the potential stratification of risk factors 
will require evaluation and will be influenced by the frequency 
of abnormal glucose tolerance in the local population.
Point of care testing and alternatives to glucose tolerance tests (GTT)
Given constraints of access, resources and capacity, and the 
need for travel, time, and costs of laboratory-based testing for 
GDM in many parts of the world, the current strategies are 
unlikely to achieve the objective of universal testing for GDM. 
There is a pressing need to develop alternative convenient, 
reliable, quick, low cost, nonfasting testing strategies to detect 
GDM at the point of care or close to home, e.g. more evidence on 
the use of handheld glucometers that can be used by community 
health workers, or noninvasive glucose testing, or use of glycated 
serum proteins as surrogate marker for hyperglycemia.
Prospective observational studies in low-resource countries to estimate 
the impact of universal GDM testing, diagnosis, and care on pregnancy 
outcomes and maternal and perinatal morbidity and mortality
Despite that GDM is one of the most common medical 
disorders of pregnancy that increases the risk for other 
pregnancy-associated medical disorders, such as pregnancy-
induced hypertension, pre-eclampsia, etc—all contributing 
to poor outcomes—screening for GDM in most low-resource 
countries is an exception rather than the rule. Its overall 
negative impact on maternal outcomes is therefore perhaps 
underestimated.
Studies looking at pregnancy outcomes in centers in low-
resource countries with similar clinical settings randomized 
to either implement a universal GDM testing, diagnosis, and 
standard treatment protocol, or the current status-quo approach, 
would help determine the true direct and indirect impact of 
hyperglycemia in pregnancy on poor pregnancy outcomes. These 
studies will help advocate for more resources and build evidence 
for action.
Treatment targets
Well-designed intervention studies for determining optimal 
glucose control for best treatment outcomes.
Fetal well-being and growth assessment
Intensity of therapy is adjusted depending on the results 
of ultrasonographic assessment of fetal growth (in particular 
measurements of fetal abdominal circumference). Research 
is required to see if this is a viable option in different resource 
settings and populations, and what other tools can be used in 
the absence of ultrasound services. Similarly, in the absence of a 
nonstress test and biophysical profile, what other measures, such 
as kick counts, can be used to assess fetal well-being?
Prediction and early testing
Hyperglycemia in pregnancy is generally diagnosed in the late 
second or early third trimester. Prepregnancy prediction may 
help address prevention and early detection, and treatment may 
potentially improve outcomes. However, there is no or limited 
evidence in this area. Well-designed studies to determine 
the most appropriate means of prepregnancy prediction and 
testing for gestational diabetes in early pregnancy and exploring 
outcomes of early treatment interventions are needed.
Long-term observational cohort studies
While there are studies to show that maternal GDM or 
diabetes in pregnancy is associated with higher risk of obesity, 
early onset T2DM, and metabolic syndrome in the offspring, 
there is currently limited or no evidence to show that good 
glycemic control during pregnancy results in reduced risk to 
offspring. Similarly, it is well known that GDM increases the risk 
of progression to T2DM but there are no studies to show whether 
the quality of metabolic control during pregnancy influences the 
level of risk or speed of progression to T2DM in mothers with 
GDM.
How to improve postpartum follow-up and preventive care
The biggest economic benefit of GDM diagnosis and care 
emerges from the ability to prevent future diabetes and metabolic 
syndrome in both mother and child through postpartum follow-
up and preventive care. Unfortunately, 75%−80% of women are 
lost to follow-up. Operational research is advocated to ascertain 
if the follow-up can be linked to the child’s vaccination program 
and well-baby clinics by identifying the mother and child high-
risk pair for more intensive counselling and follow-up.
Cost-effectiveness studies
Existing published cost/benefit analyses based on modelling 
suggested that testing women for GDM and providing care are 
cost-effective in improving pregnancy outcomes and longer-term 
maternal health. However, no large-scale long-term prospective 
cohort studies were done using actual costs and outcomes to 
assess cost-effectiveness of the different testing, treatment, and 
follow-up regimens. In the absence of such studies it may be 
useful to use local input costs data to populate available models 
such as GeDiForCE to develop cost-effectiveness estimates for 
different countries and regions.
Metabolomics, microbiome, and micro RNAs
Studies to search for metabolomic signatures in women 
with GDM and their newborns can help better understand the 
mechanisms of many congenital abnormalities as well as help 
develop diagnostic and prognostic tests to detect these changes 
and take preventive and corrective actions.
The role of gut microbiome in influencing host metabolism is 
only starting to be revealed now. Early studies show that changes 
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in gut microbial ecology can cause metabolic abnormalities 
leading to obesity and diabetes. Studies on the effect of 
pregnancy on gut microbes and its impact on metabolism leading 
to gestational diabetes and hypertension could offer solutions 
for prevention and management of these conditions. Similarly, 
the influence of maternal gut microbiome on the colonization of 
the offspring’s gut and its consequent long-term impact on their 
metabolism is an area for study that may open up opportunities 
for prevention.
The evidence implicating micro RNAs (miRNAs) in the patho-
physiology of human diseases has triggered great interest in 
developing diagnostic tests as well as modalities to inhibit or 
restore miRNA function. The recognition that specific miRNAs 
are induced by hypoxia and are commonly dysregulated in 
pre-eclampsia raises the possibility that such miRNAs mediate 
the adverse effects of placental hypoxia in pre-eclampsia. The 
connection between miRNAs, adipose tissue, and insulin resistance 
may have a role in GDM pathophysiology as well. These miRNAs 
present in maternal blood may have the potential to be used as 
biomarkers, as they are relatively stable and tissue specific.
